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1.1 Genetic landscape of tumors   
 
The majority of human cancers arise from cells that are unable to maintain genomic stability: cells 
must accumulate a significant number of genetic changes in order to progress to cancer.  
Even if genomic instability is not a requirement, carcinogenesis may proceed more quickly when 
the genome is unstable, especially if the number of changes required for progression is large and the 
genomic instability arises early (Beckman RA et al., 2006). 
Tumors demonstrate several mechanisms of genomic instability, that affect the genome at different 
levels, ranging from a single nucleotide changes to chromosome rearrangements, and the gain and 
loss of chromosome arms or aneuploidies or cryptic Copy Number Variations (CNVs). 
 
Neoplasms are characterized by Structural / Numerical, balanced/unbalanced chromosomal 
abnormalities, that often can coexist in complex karyotypes (Mietelman database). 
Not all seemingly balanced translocations turn out to be exactly balanced when analyzed at the base 
pair level. Deletions, inversions, and duplications in, and around, the translocation breakpoints may 
accompany what looks cytogenetically as balanced changes, both in malignant diseases and in 
constitutional translocations (Howart KD et al., 2011). 
 
In the genome there are also mutations involving a change in a single base pair, called Point 
Mutations that may produce Missense mutations, Nonsense mutations and Frameshift mutations 
and small deletions of a few base pairs. 
Each of these conditions may have a drastic effects on phenotypic cells expression and may be 
responsible for tumorigenesis. 
 
 
 
1.1.2 Classical cytogenetics, FISH and array CGH analysis in hematological neoplasms 
 
Classical cytogenetic analysis plays a pivotal role in the diagnosis, prognosis, identification of the 
genes involved in the development of  hematological malignancies and also influences the decision 
about the treatment of the disease (Kayser S et al., 2012).  
It is cost-effective and it is considered the gold standard in the diagnostic routine work-up of 
leukemias. 
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On the other hand, conventional karyotype has the drawbacks of poor chromosome quality and 
limited resolution.  
The generally accepted banding resolution for a routine bone marrow karyotype is 300-400 bands 
per haploid chromosome set (Gorczyca W et al., 2008). 
 
Fluorescence in situ hybridization (FISH) expands cytogenetics by identifying cryptic 
submicroscopic chromosome rearrangements that are not detectable by routine karyotyping.  
FISH analysis is highly dependent on clinical suspicion for the “choice” of the locus to analyze, 
especially in hematological cancers, where it can identify losses/gains of little regions cointaining 
onco-genes or the presence of fusion genes.   
 
In addition to the majority of abnormalities identifiable by classical cytogenetic and FISH,  
the advent of high resolution genome assays, including Comparative Genomic Hybridization 
(CGH) has enabled the detection of clinically significant submicroscopic Copy Number Variations 
(CNVs).  
 
Comparative genomic hybridization array is a high-throughput genomic screening that is able to 
detect genomic aberrations in order to redefine karyotype results and to discover submicroscopic or 
cryptic rearrangements possibly involving onco-genes. 
Microarray analysis also eliminates the need of using dividing cells and can be performed on 
uncultured speciments to provide a more accurate assesment of abnormalities (Dougherty MJ et al., 
2011).  
For these reasons, array?based platforms are now widely used in routine diagnosis, especially for 
constitutional diseases, and are gaining more and more popularity in assessing hematological cancer 
samples. 
 
 
 
1.1.3 Copy Number Variations and Loss of Heterozygosity   
 
In 2004 two landmark studies demonstrated that genomic submicroscopic variations are widespread 
in normal human genome (Iafrate et al., 2004; Sebat et al., 2004). Several analysis of this type of 
genomic variability has followed, revealing the role of DNA CNVs as an essential contributor to 
individual variability.  
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CNVs are a form of structural variations, defined as genomic segments of at least 1kb in size, 
present in a variable copy number (Shlien A et al., 2009). 
CNVs alter the number of included genes or can alter the trascription of genes by disrupting the 
start/end point, proximal or distant regulatory regions.  
 
A direct relationship between CNVs and the expression of the genes encompassed by such CNVs 
has been extensively documented both in constitutional diseases and in tumors.  
 
Although common CNVs may contain cancer-related genes and contribute to carcinogenesis, only 
the very rare CNVs (less than 1% in the population) are likely to have high penetrance for cancer 
and hematological malignancy. The role of a given CNV in cancer development depends not only 
on its gene content, but also on its interaction with other genomic variants and with environmental 
triggering agents (Krepischi et al., 2014).  
 
We must consider that not all CNVs are causative of disease or correlated to cancer development; 
many genomic imbalances are polymorphic, because commonly present in the healthy population. 
Polymorphism is defined as a genomic variant present in at least 1% of healty population.  
Polymorphism can modify the gene dosage or they may not have relevant clinical impact if the 
region involved in the deletion/amplification is gene-free.  
In constitutional diseases, the common guidelines for interpretation of the possible phenotypic 
impact of CNVs include comparison of found CNVs with CNVs in health individuals, stored on the 
Database of Genomic Variant (DGV db).  
Such polymorphic region, excluding the very common ones, must be taken into account in 
oncology because of their hypotetic predisposing significance. 
 
Loss of heterozygosity (LOH) is detectable in many forms of cancer, including leukemia and 
lymphomas and it contributes to tumorigenesis through the loss of one allele of tumor suppressor 
gene.  
Genetic mechanisms leading to LOH are highly variegated. It can be caused by deletion, which can 
involve whole chromosome or a smaller region, by mitotic non-disjunction or by mitotic 
recombination between two homologous chromosomes. 
 
LOH may be due to two kinds of events: deletions or Uniparental Disomy (UPD). 
Deletion is a loss of chromosomal region and LOH is the obvious consequence. 
8 
 
UPD refers to the situation in which both copies of a chromosome pair have originated from the 
same parent (Robinson, W.P et al., 2000). 
 
UPD can occur during gametogenesis or during early somatic cell divisions in the zygote; in these 
cases UPD is a constitutional condition.  
UPD can also occur as a consequence of somatic recombination during mitotic cell divisions 
(mitotic or somatic recombination) and thus, can be an important step in cancer development, as 
well as a contributing factor to other late onset diseases.  
 
The best choise tecnique to identify both CNVs and LOH is high resolution single nucleotide 
polymorphism  genomic microarray.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
1.2 Clinic overview of Hematologic Neoplasm  
 
Blood cancer or leukemia is a general term used to describe a group of heterogeneous neoplastic 
disorders affecting white blood cells.  
The main features of this disease is an uncontrolled proliferation of hematopoietic cells that, in the 
most of the cases, do not retain the physiological capacity to differentiate normally into mature 
blood cells.  
This differentiation arrest can occur in every maturation stage and in every cell lineage (myeloid / 
lymphoid) of blood cell differentiation, resulting in distinct forms of leukemia.  
Over the years several attempts have been made to devise a classification system for the different 
types of leukemia. Based on the patient survival rate and on the degree of maturation of the cells, 
the leukemias are classified as acute or chronic, which are further classified into lymphoid or 
myeloid types depending on the cell lineage involved in the disease (Castoldi G et al., 2007)  
 
There are four general types of leukemia, namely Acute Lymphoblastic Leukemia (ALL), Acute 
Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid 
Leukemia (CML) (Table 1).  
CLL and AML are the most common form of leukemias in adults.  
 
 
Table 2 - Types of Leukaemia  
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The two most popular classification systems presently in use worldwide are the French–American–
British (FAB) classification and the World Health Organization (WHO) classification.  
The first was established in 1976 and it is based on the morphological and cyto-chemical 
characteristics of the leukemic cells, the second was estabilished in 2001 and it has been recently 
revised.  
 
In 2016 The World Health Organization (WHO) published and reviewed a classification system for 
tumors and leukemias incorporating immunophenotypic and clinical information to define a 
clinically and biologically relevant disease nomenclature. Genetic investigation is essential part of 
the diagnostic and prognostic field.    
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1.3 Acute Myeloid Leukemia (AML) 
 
Acute myeloid leukemia (AML) is defined as a clonal disorder caused by malignant transformation 
of a bone marrow–derived, self-renewing stem cell or progenitor, which demonstrates a decreased 
rate of self-destruction as well as aberrant, and usually limited, differentiation capacity. These 
events lead to an increased accumulation of these malignant myeloid cells in the bone marrow and 
other organs by these malignant myeloid cells.  
AML is nowadays considered a disease of the elderly, based on the median age at the diagnosis (67 
years) and it is also slightly more common in males than in females.  
The presenting symptoms of AML are remarkably variable, but pallor and redness resulting from 
anemia, easy bruising/spontaneous bleeding due to thrombocytopenia, fever/ infections caused by 
the lack of normal leukocytes are often present.  
 
The FAB classification system represents the first attempt to distinguish between the different types 
of AML and it defines eight subtypes (M0 to M7).   
According to the WHO classification, the current major subtypes of myeloid neoplasms and acute 
leukemias are: AML with recurrent genetic abnormalities, AML with myelodysplasia-related 
changes, Therapy-related myeloid neoplasms, AML not otherwise specified NOS, myeloid 
sarcoma, Myeloid proliferations related to Down Syndrome, Blastic plasmacytoid dendritic cell 
neoplasm and Acute leukemias of ambiguous lineage.  
The lastest update of the WHO classification provides few changes to the existing disease 
categories and introduces a new category called “Myeloid neoplasm with germline predisposition” 
(Dohner et al., 2016). 
 
AML can arise de novo or secondarily either due to the progression of other diseases, like 
Myelodisplastic syndrome. Up to 15% of patients affected by AML develop the disorder after 
treatment with cytotoxic chemotherapy.   
 
Development of AML has also been correlated to the exposure to a variety of environmental agents, 
with a strong correlation between exposure history and cytogenetic abnormalities. Radiation, 
benzene inhalation, alcohol use, smoking, dyes, and herbicide and pesticide exposure have been all 
included as potential risk factors for the development of AML (West RR et al., 2000; Crane et al., 
1996) 
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1.3.1. Chromosomal aberrations in AML 
 
Non-random chromosomal aberrations, which often result in gene arrangements, can be detected in 
approximately 50% of newly diagnosed AML patients. According to SIGU (Italian Society of 
Human Genetics) and international guidelines, chromosomal aberration in AML must be clonal and 
thus present in at least 3 cells (in case of monosomies) or in at least 2 cells (in case of trisomies or 
structural rearrangements). 
Actually cytogenetics abnormalities are an important diagnostic and prognostic factor in predicting 
remission rate, relapse, and overall survival of AML patients (Martens JHA et al., 2010; Dohner et 
al., 2015).  
 
Several chromosomal abnormalities such as monosomies or partial/entire deletions of chromosomes 
are common in AML (Byrd et al., 2002). The most common abnormalities in AML are:  
 
? Losses affect mostly chromosome 5 and 7 (-5/5q-, -7/7q-); -17/17p-, 18/18q-, 12p-, -16/16q- 
are also frequently found.  
? Gains generally affect 8/8q, (+8/+8q), +21/+21q, +11q, +22q (Rucker et al., 2006).   
 
All the chromosomal aberrations in leukemia are reported in the Mitelman database (Mitelman 
database of chromosome aberrations and gene fusion in cancer. Last update November 2016). 
 
The most commonly identified abnormalities are reciprocal translocations, which create a fusion 
gene encoding a chimeric protein. The most frequent chromosomal aberrations and their 
corresponding fusion genes are shown below.  
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Translocations Oncofusion protein 
? t(8;21)(q22;q22) AML1-ETO 
? t(15;17)(q22;q21) PML-RARα 
? inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBF□-MYH11 
? der(11q23) MLL-fusions 
? t(9;22)(p21.3;q23.3) BCR-ABL1 
? t(6;9)(p23;q34.1) DEK-CAN 
? t(1;22)(p13.3;q13.3) OTT-MAL 
? t(8;16)(p11;p13) MOZ-CBP 
? t(7;11)(p15;p15) NUP98-HOXA9 
? t(12;22)(p13.3;q13.3) MN1-TEL 
? inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) RPN1-EVI1 
? t(16;21)(p11;q22) FUS-ERG 
(Chandra Kumar C et al., 2011; Mrózek K et al., 2009) 
 
 
 
 
1.3.2 Most recurrent and cryptic CNVs in AML  
 
In addition to large chromosomal rearrangements, cryptic genomic changes and molecular changes 
have also been correlated to the development of AML.  There are many studies aimed at detecting 
recurrent or individual copy number changes.   
Losses are generally more frequent than gains. 
The most recurrent submicroscopic aberrations reported in literature are listed in table 2 and they 
are showed in figure 1.   
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CHROMOSOME CNV GAIN Cytoband 
CNV LOSS 
Cytoband 
1 
p36.13 
p35.3 p36 
2 q33.1 q33.2 
3 // p14.1 q21.1 
4 // 
q13.1 
q22.2 
q24 
5 
p15.33 
q13 
q35.1 
q31 
q31.2 
q32 
6 q23.3 q24.1 q27 
7 // 
p14.1 
p12.2 
q11.21 
q22 
q31 
q31.32 
q32.3 
q35q36 
8 
q21.2 
q23.2 
q24.12 
q24.13 
q24.13q24.21 
q23 
9  p21.3 p13.2 
10  q11.2 
11 
q12q14 
q23.3 q25 
12 p13.32 p13.1 p13.1p12.3 
13  q14.2 q14.3 
14  q31.1q32.11 
15 
q11.2 
q21.3 q21.3 
16  
q22 
q22.1 
q23.1q24.3 
17 q12 
p13.2p13.1 
p13.1 
p11 
q11 
q11.2 
q24.3 
18 // p11.2 q12.3q21 
19 
p13.2 
p13.1 // 
20 // q13.12 q12q13.1 
21 q22.2 q22.12 
 
 
Table 2 - Most recurrent CNVs in AML (Paulsson K et al., 2006; Walter MJ et al., 2009; Rücker FG et al., 2006; 
Kjeldsen et al., 2015; Zhang R et al., 2015). 
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Figure 1 - Ideogram with the most recurrent CNVs in AML. Deletions are represented in Red, Duplications in green 
(Paulsson K et al., 2006; Walter MJ et al., 2009; Rücker FG et al., 2006; Kjeldsen et al., 2015; Zhang R et al., 2015).  
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Cytogenetically normal AML accounts for about one-half of total AML (Dohner et al., 2010). 
Karyotypically normal AMLs (NK-AML) are prognostically various and generally classified as an 
intermediate risk; therefore, the ability to identify molecular cytogenetics changes in patients with 
NK-AML will deepen our understanding of the genetics behind AML and can open the possibility 
to develop more specific therapies as well as improved patient classification schemes. 
To date, only few studies have evaluated CNVs-SNPs in patients with NK-AML.  
Tyybakinoja et al., in 2007 investigated Copy Number aberrations in 26 NK-AML patients and he 
detected novel cryptic aberrations in 22 out of 26 cases. Molecular karyotype showed deletions in 
1q41 8q24.11, 12p12.2, 12p13.2, 18q21.32 and duplications in 3p21.3 and 8q24.12q24.21.   
 
Akagi et al., in 2008 found some CNVs in NK-AML: Gains were reported to affect chromosomes 
1q43, 18q21.2, 8q24.12-q24.21; found Losses were located on 2p23.1, 2q36.2, 3p26.3, 4q24, 
8p23.3, 9p21.3-p21.2, 12p13.31p13.2, 14q21.2, 17q11.2 and 21q21.2. 
 
Bullinger et al., in 2009 studied 157 AML NK-patients with 50K and 500K affymetrics SNP array 
and observed both SNPs and CNVs. Genomic losses were more frequently identified than gains. 
The following bands were reported as recurrent genomic deletions: 3p14.1-p13, 6q27, 8q23.3, 
10q11.21, 11q25, 12p13.2, and 15q21.3, that harbor genes FOXP1 and RYBP (3p14.1-p13) 
RPS6KA2 (6q27), TRPS1 (8q23.3), HNRPF(10q11.21), ETV6 (12p13.2) and RFXDC2 (15q21.3).  
Kim et al., in 2012 studied CNVs in 30 AML patients with normal karyotype and the association 
between the alterations and the response to treatment. He found gain in chromosome 4, 8 and 17, 
and he observed many losses ecompassing AML related gene, as shown below: 
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CHROMOSOME CNV GAIN 
Cytoband 
AML relevant gene  
4 q32-2 // 
8 p11.1 
17 q21.32 
CHROMOSOME CNV LOSS 
Cytoband 
AML relevant gene  
1 p36.33p36.32 
p36.31 
HES5, PRDM16 
TNFRSF25 
2 q31 MTX2 
4 p16.3  
5 p15.33 TERT 
7 p22.3 
p15.2 
q36.1 
ABCB8 
8 p21.3 
q24.3 
PTP4A3 
9 q33.3 PBX3 
 q34.2q34.3  
10 q26.3 VENTX 
11 p15.5  
12 q24.33  
14 q32.33 AKT1, KIAA0284 
16 p13.3 
q24.1 
q24.2q24.3 
           ABCA3 
 
CBFA2T3, FANCA 
17 p13.2 
q12 
q25.3 
 
MLLT6 
CD7 
18 q23  
19 
 
p13.3 
p13.11 
q13.11 
q13.31q13.32 
q13.42 
q13.43 
PRTN3 
 
CEBPA 
20 q13.33  
21 q22.3 
q11.1 
q13.31 
q13.33 
 
 
 
Spina et al in 2015 studied 36 patients with AML and normal karyotype. CGH array showed no 
alterations in 22 out of 36 cases and, in the remaining 14 cases, it allowed the detection of 43 
imbalances: 24 duplications and 19 deletions, that were not previously identified through CC and/or 
FISH. 
Some of these alterations were highly repetitive, as they were found in more than 3 patients: gain of 
19q13.12 (8/14 cases), gain of 7q35 (5/14 cases) and loss of 3p14.2 (2/14 cases).  
 
About 10 years ago genome-wide analysis of single nucleotide polymorphisms in AML patients has 
revealed that about 20% of them exhibited large regions of homozygosity that could not be detected 
by visible chromosomal abnormalities in the karyotype. 
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Some authors applied SNP array in AML cases and identified partial uniparental disomy (pUPD) in 
a relevant percentage of cases.   
 
The most recurrent sites of loss of heterozygosity found in AML patients affected chromosomes 
11p, 11q, 13q (Raghavan et al., 2005; Gupta et al., 2008; Gronseth et al., 2015).  
Additional recurrent abnormalities were located on 2p, 2q, 11p, 11q, 17p, 17q, 21q and Xq loci 
(Raghavan et al., 2005; Gronseth et al., 2015). 
 
More recently, Bullinger and colleagues used 50K and 500K Affymetrix SNP arrays to examine 
157 cases of cytogenetically normal AML.  
The cohort showed that 12% UPDs most commonly involved the chromosomal regions 6p, 11p, 
and 13q; all UPDs were >29 Mb. 
The UPDs were associated with mutations in NPM1 or CEBPA, which suggested, according to the 
findings of Fitzgibbon and colleagues, that UPDs may affect genes that are critical for 
hematopoiesis (Bullinger et al., 2009; Fitzgibbon et al., 2005). 
 
All these studies confirmed the clinical relevance as well as prognostic significance of CNV/SNP 
lesions in NK- AML, which would allow a better prognostic stratification of AML patients and 
more appropriate treatments of the disease.  
 
 
 
1.3.3 Genic mutation in AML  
 
During the last decade, several studies have shown that the presence of specific gene mutations 
and/or changes in gene expression can lead to further classify AML cases and can have an effect on 
the patients’ prognosis. Key molecular abnormalities have been identified and are now used to 
predict outcomes; moreover, they help to guide the treatment of AML patients (Lindsley RC et al., 
2015; The Cancer Genome Atlas Research Network, 2013). 
Genetic mutations in AML are classified into two main categories:  Class I and II. The first results 
in the activation of pro-proliferative pathways and survival, the second impairs normal 
hematopoietic differentiation for leukemia development and apoptosis (Kavianpour et al., 2016). 
Class I mutations involve gene such as FLT3, K/NRAS, TP53 and c-KIT, which are found in 
19 
 
approximately 28, 12, 8 and 4% of cases, respectively.  
Class II include NPM1 and CEBPA mutations, which are found in approximately 27% and 6% of 
cases, respectively.  
Alterations in genes involved in epigenetic regulation have recently emerged as a third class of 
mutations, with downstream effects on both cellular differentiation and proliferation.  
These include mutations in the DNA-methylation related genes DNMT3A, TET2, and IDH-1 and 
IDH-2, which are found in more than 40% of AML cases (I De Kouchkovsky and M Abdul-Hay 
2016) 
Patients are generally grouped into three risk categories (Favorable, Intermediate, Adverse), based 
on both cytogenetic and molecular aberrations (Figure 2).  
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Figure 2 - 2017 European LeukemiaNet risk stratification by genetics  a 
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1.4 Post-Transplantation Lymphoproliferative Disorders, PTLD 
 
 
Post-transplantation lymphoproliferative disorders (PTLD) are an aggressive complication of both 
solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) in the setting 
of immunosuppression.  
Immunosuppressive induction and maintenance regimens were carried out to prevent organ graft 
rejection by the recipient's immune system.  
On the downside of pharmacological immunosuppression, a decreased immunological surveillance 
of infections and malignancies is observed.  
Pediatric and adolescent patients after transplantation have an increased risk of cancer development, 
which is estimated to exceed the normal population up to 45-fold, depending on the type of cancer 
(Engels EA et al., 2011) 
 
The incidence of PTLD largely depends on the type of organ transplanted, the respective intensity 
of immunosuppression, and the recipient's viral status prior to transplantation.  
 
Primary EBV infection may develop in an EBV-seronegative recipient who receives an allograft 
from an EBV-seropositive donor, and it is probably recognized the most important risk factor for 
PTLD development and often occurs within the first year after transplantation. 
It is therefore not surprising that in general, PTLD rates are reported to be higher in pediatric 
transplant recipients than in adult transplant recipients (Jamali FR et al., 2007). 
 
The type of transplant allograft is another relevant risk factor that influence the probability to 
develop PTLD.  
Reported rates of PTLD are higher in heart, heart-lung, and small bowel transplants compared to 
kidney and liver transplants. This presumably reflects in part the need for more intense 
immunosuppression to maintain certain types of allografts. The PTLD after Bone Marrow 
transplantation ranges from 0.5% to 1.0% (Lawrence T et al., 2007). 
 
Other risk factors implicated in PTLD include Hepatitis C, Cytomegalovirus (CMV) and age 
younger than 10 or older than 60 years (Buda et al., 2000; Cockfield et al., 2001; Opelz G et al., 
2004). 
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The combination of multiple risks factor can increase the risk of PTLD up to 500-fold compared to 
patients with no risk factors (Walker Rc et al., 1995). 
 
PTLD include a wide range of diseases, from benign hyperplasia to malignant lymphomas that can 
arise from B cell. More than 80% of these are EBV correlated although there are some cases of non-
EBV correlated PTLD. EBV negative PTLD typically appears as a late complication of 
transplantation with more aggressive features.  
 
The WHO classification clearly identifies PTLD, grouping them into main categories:  
Early lesions, polymorphic PTLD, monomorphic PTLD, and classical Hodgkin lymphoma-type 
PTLD, as presented below: 
 
Early Lesions (5% ) Plasmacytic hyperplasia PTLD  and Infectious mononucleosis PTLD 
Polymorphic (PTLD 15-20%) 
Monomorphic PTLD  
? B-cell neoplasms  (>70%) Diffuse large B-cell lymphoma, Burkitt lymphoma, 
Plasmacytic neoplasm 
? T-cell neoplasms   (<5%) Peripheral T-cell lymphoma NOS, Hepatosplenic T-cell 
lymphoma 
Classical Hodgkin lymphoma-type PTLD (<5%) 
Table 3 - the Who classification of PTLD 
The most common malignant PTLD subtype are Post-transplant diffuse Large B-cell lymphoma 
(PT-DLBCL), Burkitt lymphoma (PT-BL) and plasmablastic lymphoma (PT-PBL).  
 
CGH array in PTLD  
 
- Post-transplant diffuse large B-cell lymphoma (PT-DLBCL) 
 
Genetic studies have demonstrated that Post transplantation-DLBCL (PT-DLBCL) has some 
somatic recurrent genomic aberrations such as gains of 8q24 harboring MYC, 3q27 harboring BCL6, 
18q21 harboring BCL2, 7q harboring CDK6 and loss of 17p13, harboring TP53.  
Moreover, PT-DLBCL presents Gain of chromosome 2p24-25, 5p, 9q22, 12q22 13q32,18q21 and 
Non-random losses involved 1p36, 4q, 17p13, 17q23q25, Xp (Poirel HA et al., 2005) 
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EBV+ and EBV- PTLD are rarely distinguished, but some studies have found some differences: 
 
EBV-  PT-DLBCL was associated with gains of 3/3q (encoding FOXP1) 7p, 7q and 11q24-q25, 
18q, and loss of (4q25-q35) 6q23.3/TNFAIP3 and 9p21/CDKN2A.  (Rinaldi A et al., 2010; Lenz G 
et al., 2008, Moscio J et al., 2016)  
 
EBV+  PT-DLBCL frequently carry trisomies of chromosomes 9 and 11 (Djokic M et al., 2006)  
and gain of 9p24.1, that harbors PDL1, PDL2 and JAK2 (Yoon et al., 2015).  
In one study, aberrant MYC was detected in 40% of PT-DLBCL, independently of the EBV status 
(Cerri M et al., 2004)  
 
 
P
T
-D
L
B
C
L
 
GAIN LOSS 
8q24 (MYC) 17p13 (TP53) 
3q27 (BCL6) 17q  
18q21 (BCL2) 4q 
7q (CDK6) Xp 
5p  
 
P
T
-D
L
B
C
L
 +
 E
B
V
 s
ta
tu
s 
EBV negative 
GAIN  LOSS  
7p/q 4q25-q35 
11q24-q25 6q23.3 (TNFAIP3) 
3q (FOXP1) 9p21 (CDKN2A) 
EBV positive  
GAIN LOSS  
+9 
// +11 
9p24.1 (PDL1/2 JAK2) 
Table 4 – Schematic representation of chromosomal aberration in PT-DLBCL patients 
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- Burkitt Lymphoma  
 
The hallmark of BL and also PT-BL with Burkitt morphology is the presence of translocations 
t(8;14)(q24;q32) involving MYC gene (Djokic M et al., 2006). 
Recently an 11q aberration (Gain/Loss) was detected in both MYC-negative and positive high-
grade B-cell lymphomas resembling BL without MYC rearrangements, both at morphological as 
well as the molecular level. (Salaverria I et al., 2014) (Havelange V et al., 2016)  
 
- Plasmablastic lymphoma PT-PBL 
Very little is known about the molecular-genetic basis that drives PT-PBL. One study showed that 
up to 47% of EBV+ AIDS-related PBLs are marked by MYC translocations (Delecluse HJ et al., 
1997) Array-CGH showed that the genomic aberrations pattern of PBL is similar to that found in 
DLBCL. 
 
 
In conclusion, non-random chromosomal imbalances are present in PTLD. The open question is the 
role of such lesions in the development and progression of this PT-induced lymphoproliferative 
disorders (Porel HA et al, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
2-AIM OF THE STUDY  
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2.1 AML Patients  
 
The first aim of the present study was to characterize, by array CGH analysis, the presence of 
cryptic copy number variants (CNVs) and LOH regions through whole-genome oligonucleotide 
array CGH+SNP analysis in AML patients with apparent normal karyotype; moreover, this study is 
aimed at identifing the associations of such alterations with biological / clinical features and 
outcome.  
The second aim was to demonstrate the clinical utility of aCGH in patients with different subtypes 
of AML.  
 
 
 
2.2 PTLD Patients  
 
The aim of this study was to investigate by array-CGH 180K, the presence of constitutional CNVs 
in  the patients that developed a post-kidney transplantation lymphoproliferative disorder (PTLD). 
The results have been compared with those found in patients that did not develop 
lymphoproliferative disorders after a renal transplantation.  
The hypothesis of a role of constitutional CNVs as predisposition factors for such cancer 
development has been recently suggested by different authors (Roland P K et al 2010; Adams S et 
al., 2009) . 
Park et al., in his study identified rare germline copy numbers variations overrepresented in five 
human cancer (brain, ovarian, colon-rectall, renal) and this findings potentially serve as clinical 
useful markers conferring increased cancer risk.  
Krepischi et al.,  suggested that a duplication Xq27.2 and a deletion of 13q31.2-q31.3 can 
predispose to pediatric Hodgkin’s Lymphoma and  Acute Lymphoblastic Leukemia respectively.  
 
Our  hypothesis is that  as yet unknow germinal CNVs may contribute as predisposition factors to 
the development of PTLD in post transplanted patients. 
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3 – METHODS AND MATERIALS 
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3.1 Patients 
 
Two groups of patients were studied: the first group consisted of 26 de novo AML patients ( 32-78 
years). 
Diagnosis of de novo AML was estabilished at the hematology Department of Ospedale di Circolo 
e Fondazione Macchi - Varese directed by Prof. Francesco Passamonti. Clinical diagnosis was 
performed according to FAB criteria. 
The most common remission induction regimens for AML include a drug called Idarubicin 
(12mg/mq/die, day 1-3) and Daunorubicin / Cytarabine (100mg/mq/die, day 1-7)  This is often 
called the "3+7" regimen.  
Resistant AML is considered when, after the first induction cycle of chemotherapy, more than 5% 
of blasts are present in the bone marrow.  
Consolidation or post-remission chemotherapy often includes 3 or 4 cycles of  high-dose 
Cytarabine. 
 
The second group of patients consisted of  22 kidney-transplanted pediatric patients: part of them 
developed  lymphoproliferative disorders post transplantation. Some patient showed EBV Viral 
Load (High: more than 1000 copies/ml; Low: less than 1000 copies/ml).  
The patients come from Pediatric  Department of San Matteo Hospital - Pavia, by courtesy of 
Prof.ssa Patrizia Comoli.  
 
 
 
3.2 Standard cytogenetics 
 
Bone marrow aspirate (sternal or iliac crest) of patients with AML was obtained at the time of the 
diagnosis, cultured and harvest (24 and 48 h cultures in Chang BMC and Chang Marrow culture 
media - Irvine Scientific, Santa Ana, USA) using standard cytogenetic protocols according to SIGU 
Guidelines.  
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Briefly: 
 
- Dispence 10 ml of Chang BMC/Chang Marrow culture media into a tubes and add 0,5ml of bone 
marrow sample. Inoculate al 37°C for 24 – 48 hours; 
- Inject the cultures with 50 ml of Colcemid (10 ml/ml); 
- Recover the cells by low-speed centrifugation (2000rpm, 5 minutes) and stuck off the supernatant 
to around 3mm above the cell pellet; 
- Flick the rube to distribute the cell and add the hypotonic solution KCl (0,56%, 0.075M) for 20 
minutes; 
- Centrifugate at 2000rpm 5 minutes and remove the supernatant; 
- Carefully add 5 ml of fresh Fixative (3:1 ratio of methanol:acetic acid) to the cells while 
vortexing. Then add 5 ml more of fixative without vortexing for a total of 10 ml. 
- Centrifuge at 2000rpm for 5 minutes. Remove supernatant and resuspend cells. Add 5 ml of 
fixative to each tube. Repeat this procedure twice.  
- Store the cell at 4 °C  
- After gently resuspending the pellet, pipette three drops of the cell suspension from a distance of 
about 2 cm onto a slide which is tilted at an angle of about 45° and allow the suspension to roll 
across the slide. 
- After thoriugh drying the slides may be stained in a fresh solution of Quinacrina dihydrochloride 
for at least 15 minutes 
- Slides are ready for examination. 
 
 For each case a minimum of 20 metaphases were visualized under microscope and analyzed using 
QFQ-banding at a resolution of 350bands. 
 
The chromosomal aberrations observed were described according to ISCN (Intenational System of 
Cytogenetic Nomenclature).  
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3.3 Fluorescent in situ Hybridization, FISH  
 
FISH was performed according to general procedural recommendations by Cytocell OGT. 
 
Briefly, the main steps are: 
 
 - dehydrate the slide in an ethanol series (70%-85% and 100%) each for 2 minutes at room 
temperature  
- pre-denaturation of the sample slide and probe at 37°C for 5 minutes  
- denaturation at 75°C for 2 minutes 
- hybridization, overnight at 37°C in a humidity chamber. 
- post hybridization washes and air-dry at room temperature  
- drain the slide and counterstaining with DAPI/Antifade onto each sample before viewing with a 
fluorescent microscope. 
 
 
Temperature and buffer concentration (stringency) of hybridization/washing are important: lower 
stringency can result in a non-specific binding of the probe to other sequences, and higher 
stringency can instead result in a lack of signal, as well as an incomplete denaturation step. 
 
 
 
3.4 Comparative Genomic Hybridization Array, CGH- ARRAY  
 
 Genomic DNA was isolated and purified from mononuclear/blasts cells by using Ficoll-paque 
gradient centrifugation (Biochrom GmbH Leonorenstr 2-6 – Berlin, Germany) and from bone 
marrow-derived fibroblasts.  
 
DNA was obtained with DNA mini Kit Quiagen extraction Kit, following the manufacters protocol 
(QIAGEN, Hilden, Germany www.qiagen.com). 
 
Sex-matched normal human DNA (Kreatech – Amsterdam, Holland) was used as reference.   
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The OD 260/280 method on a photometer (Nanophotometer IMPLEIN, Munchen Germany) was 
employed to determine the appropriate DNA concentration and its high quality.  
 
Array-CGH analysis was performed by using Oxford Gene Technology’s (OGT) CytoSure 
Hematological Cancer + SNP 8x60k array platform, containing about 60 000 probes (1 probe every 
68Kb in high density gene regions, 1 probe every 117Kb in the backbone; LOH resolution is 30Mb) 
and OGT CytoSure ISCA v2 4x180k array platform, containing about 180 000 probes (1 probe 
every 19Kb in high density gene regions, 1 probe every 25Kb in the backbone). 
 
The experiment was performed according to the Cytosure OGT protocols.  
 
Briefly: 
Genomic DNA (1 μg) was mixed with 10 μl of Random primer and Reaction buffer solutions  
 and MilliQ water to a total volume of 18 μl. The mix was denaturated at 99° C 
 for 20 minutes and then incubated in ice  for 5 minutes.  
 
Each sample was added with 10 μl of nucleotide mix, 1 μl of Cy3-dCTP (test sample) or 1 μl of 
Cy5-dCTP (reference sample) and with 1μl of Exo-Klenow. The samples were incubated at 37°C 
for at least 2 hours and then subsequentely purified using Amicon Ultra 30K purification kit 
(Millipore).  
 
Test and reference DNA were pooled and mixed with 5 μg of Human Cot I DNA (1mg/ml), 11 μl of 
Blocking buffer (Agilent Technologies) and 55 μl of Hybridization buffer (Agilent Technologies). 
Before hybridization to the array.  
 
After samples’ denaturation at 94°C for 3 minutes and 37°C for 30 minutes, probes were applied to 
the slide using an Agilent microarray hybridization station. Hybridization was carried out for 24/40 
hrs at 65°C in a rotating oven (20 rpm). The array was disassembled and washed according to the 
manufacturer protocol with wash buffers supplied by Agilent. 
 
The slides were dried and scanned at 2mm using Innoscan 710 Microarray scanner (Carbone, 
France).  
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The software automatically determines the fluorescence intensities of the spots for both 
fluorochromes performing background subtraction and data normalization, and compiles the data 
into a spreadsheet that links the fluorescent signal of every oligo on the array to the oligo name, its 
position on the array and its position in the genome.  
 
The genomic locations were based on Genome Reference Consortium GRCh37. 
 
Aberration segments were reviewed using GRCh37 hg19 of UCSC Genome Browser 
(http://genome.ucsc.edu/index.html).  
 
We annotated all detected copy number variations (CNVs) and CNV-encompassed genes across 
public databases: Genomic Variants Database (DGV) (http://dgv.tcag.ca/dgv/app/home), 
DECIPHER (https://decipher.sanger.ac.uk/), Clinical Genome Resource (ClinGen) and ISCA 
(http://www.clinicalgenome.org), OMIM (http://www.omim.org), PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed).  
 
 
 
3.5 Polymerase Chain Reaction (PCR) and Reverse-Transcription Polymerase Chain 
Reaction (RTPCR) 
 
RNA was isolated with RNeasy Mini Kit QIAGEN, according to manufactures' recommendations 
(www.QIAGEN.com). 
 
cDNA was obtained with "Superscript VILO cDNA synthesis kit" by Invitrogen (Thermofisher), 
according to manufacturer’s recommendations (www.thermofisher.com) 
 
Translocation and inversion are performed following the "Experteam Translocation KIT" 
manufacturer’s recommendations (www.experteam.it). 
 
NPM1 and FLT3 analysis were performed according to literature (Falini B et al., 2005 New 
England Journal of Medicine; Nakao M et al., 1996 Leukemia vol.10) 
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3.6  Sanger sequencing  
 
 DNA sequencing is a post-PCR analysis, that permit to identify and/or confirm mutations. 
 
All the sequencing reaction in our laboratory are performed by using Big Dye Terminator v1.1 
(Applied Biosystem _ Forster City CA) and run by Abi Prism 310 genetic Analyzer (Applied 
Biosystem _ Forster City CA).  
 
To detect raw data we commonly use Sequencing analysis v5.6 software (Applied Biosystem _ 
Forster City CA). 
 
 
 
3.7 Bone marrow-derived Fibroblast cells culture  
 
 
Bone marrow was collected and anticoagulated with heparin. 
 
Briefly,  the cell were washed with PBS and then were resuspended in low glucose DMEM medium 
containing 10% fetal bovine serum and 1% penicillin-streptomycin. 
 
The cell was inoculated into cell culture flask with 1x106 cell/mL density and cultured (37oC, 
5%CO2). 
 
After 4-6 days, the culture medium was replaced to remove the non-adherent cells, the ramaining 
aderent cells  are mostly fibroblasts.  
 
When the cellular  confluence rate 80%, the cell were collected for DNA extraction to performe 
aCGH. 
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4 – RESULTS 
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4.1 AML PATIENTS  
 
From a series of hematologic malignancies sent for diagnostic purpose to the laboratory of 
Citogenetica e Genetica Medica (Ospedale di Circolo e Fondazione Macchi, Varese) in the period 
2010-2016, we selected 26 AML samples on the basis of the availability of hight quality DNA or 
fixed cells suitable for a-CGH / SNP-CGH procedure. 
 
Diagnosis of primary AML was estabilished at the Hematology Department of our hospital by 
conventional morphology, histologic, cytochemical, immunophenotypic and genetic criteria, 
following the WHO guide.   
 
We divided cases into 2 groups based on conventional karyotypes and, sometimes, FISH:  
group A consisted of 22 patients with normal karyotype; group B consisted of four patients with 
complex karyotype.  
 
Karyotype was reported based on the analysis of at least 20 metaphases.  
Cytogenetic nomenclature followed ISCN criteria enforced at time of diagnosis.  
 
An informed written consent was obtained during the onset of the disease of all patients; clinical 
information, such as age, sex, cytogenetic/molecular markers, history and survival were 
retrospectively obtained.  
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4.1.1 Group 1 - AML with normal karyotype  
 
QFQ-banding karyotype analysis of non-stimulated bone marrow samples (24-48h), at the onset of 
AML disease, was normal in all 22 patients analyzed (46, XX or 46, XY) in a mimimun of 20 
observed metaphases.  
 
To assess the possible existence of unbalanced chromosomal abnormalities and/or cryptic 
rearrangements, we performed in all AML patients CGH array analysis + SNP with 8X60K 
Hematological cancer SNP (Cytosure OGT) and the following molecular tests, when requested by 
haematologists during the onset of AML: t(15;17), t(8;21), inv(16), NPM1, FLT3, IDH1/IDH2.  
 
Copy number changes frequently present in healthy population and well-know as common 
polymorphisms are not reported in this study.  
 
Table 5 describes the genomic imbalances (CNV Gain and Loss and LOH) and the results of 
molecular analysis in tested patients. 
Empty cells indicate that the molecular test was not required.  
 
11 out of 22 patients showed a normal genomic setting, without sub-microscopic aberrations 
(Patient number 3, 5, 7, 11, 12, 13, 14, 15, 16, 18 and 20).   
Among them, seven cases (Patient number 3, 12, 13, 14, 15, 16 and 18) showed only molecular 
genic mutation: NMP1 was found mutated in patients 15, 16 and 18; FLT3 in patients 13 and 14.  
Patient 3 and 12 were found mutated in both NPM1 and FLT3 genes.  
Four cases (Patient number: 5, 7, 11 and 20) resulted normal also for molecular tests requested.  
Two cases (Patient number 1 and 21) showed CNVs and Genic Variation; two cases (Patient 9 and 
19) showed only LOH; three cases (Patients number 4, 10 and  17) only CNVs.   
Three cases (Patient number 6, 8, 22) showed both CNVs and LOH and one case (Patient 2) showed 
CNVs, LOH and genic mutation (Table 6). 
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COPY NUMBER VARIATION, CNV 
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LOCATION SIZE POLIMORPHISM LOCATION SIZE POLIMORPHISM LOCATION SIZE 
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1
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n
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(
1
6
)
 
N
P
M
1
 
F
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T
3
 
1 M, 69 3q26.32q26.33 404 Kb  // // // // //    M* n 
CR, RE, 
PR, CR, 
RE, in 
treatment 
2 F, 73 // // // 7q22.1 40Kb Partial Chr X 106 Mb  n n M* n R, RE, D 
3 F, 71 // // // // // // // //  n n M* 
M
* 
R in 
treatment 
4 F, 70 Chr 10 132 Mb NO // // // // //  n n n n CR in FU 
5 M, 70 // // // // // // // //   n n n PR, D 
6 M, 70 Chr 4 186 Mb NO // // //  11q13.2q25 66 Mb  n n n n R, D 
7 M, 42 // // // // // // // // n n n n n PR, RE, D 
8 M, 43 Chr 13 96Mb NO 17q21.31 632 Kb Partial 11q13.2q25 69Mb  n  n n CR in FU 
9 F, 56 // // // // // // 2p25.3p11.2 83 Mb    n n PR, RE, D 
10 M, 77 10q25.1 2,4 Mb Partial // // // // // n     R, D 
11 M, 59 // // // // // // // //  n n n n CR 
 
12 M, 53 // // // // // // // //  n n 
M
* 
M
* CR, RE, D 
 
13 M, 67 // // // // // // // //  n n n 
M
* CR in FU 
14 F, 48 // // // // // // // //  n n n M* R, BMT, D 
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15 M, 52 // // // // // // // //  n n M* n R. in FU 
16 F, 74 // // // // // //  // //  
n n 
M
* 
n CR, RE, D 
17 M, 53 
4p16.3              
7q22.1                  
17q21.31 
53Kb        
82 Kb   
21Kb 
Partial 
NO 
NO 
 
-Y 56 Mb NO // //    n n CR in FU( High Risk) 
18 M, 41 // // // // // //  // //  n n 
M
* n 
CR, late 
RE, BMT, 
CR in FU 
19 M, 78 // // // // // //  4q21.3q35.2 102 Kb  n n n n 
R in 
treatment 
20 F, 71 // // // // // // //   n n n n R 
21 M, 75 Chr 1q Chr 8 
107 Mb 
143 Mb 
NO 
 // // // // //    
M
* n 
R in 
treatment 
22 F, 75 Chr 16p 32kb NO  
4q32.1q34.3 
Chr 5q 
Chr 7 
12p13.2p12.1 
Chr 16q 
17Mb 
80Mb 
253 Mb 
57Mb 
11Mb 
44Mb 
NO // //  n n n n R, in treatment 
 
 
Table 5 - Microarray abnormalities detected by Cytosure OGT 8x60K Hematological cancer CGH + SNP and results of molecular tests. 
Abbreviations: M (male), F (female), % Polymorphism (% POL), Mutated (M*), Normal (n), Complete Remission (CR), Partial Remission (PR), Relapsed (RE), Refractory (R), 
Deceased (D), Follow Up (FU)  
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Table 6 - Summary of Patients without sub-microscopic 
aberration and Clinical outcome . 
Abbreviations: M (male), F (female), Relapsed (RE), 
Refractory (R) Complete Remission (CR) 
 
 
 
 
 
 
 
 
 
 
 
PATIENT 
RESULTS 
CLINICAL 
OUTCOME 
aneuploidy/entire 
arm imbalances 
 
CNVS  LOH  genic mutation 
1  gain 3q26.32q26.33   NPM1 
CR,  RE, PR, CR,  
RE  
2  loss 7q22.1  NPM1 R, RE, D 
4 +10     CR 
6 +4    11q13.2q25   R, D 
8 +13    11q13.2q25   CR 
9   2p25.3p11.2   PR, RE, D 
10  10q25.1   R, D 
17 -Y 
gain 4p16.3 
gain7q22.1 
gain17q21.31 
  CR 
19   4q21.3q35.2   R 
21 +8 +1q    NPM1 R 
22 
-7 
loss5q 
+16p 
-16q 
loss4q32.1q34.3 
loss12p13.2p12.1  
 
  R 
Table 7- Summary of Patients with entire/total aneuploidy/monosomy, genic mutation and Clinical outcome . 
Abbreviations: Relapsed (RE), Refractory (R) Partial Remission (PR) Complete Remission (CR) Deceased (D) 
 
 
PATIENTS 
SEX 
and 
AGE 
CLINICAL 
OUTCOME 
R RE CR 
Normal  
5 M, 70 X   
7 M, 42  X  
11 M, 59   X 
20 F, 71 R   
Genes 
mutations  
3 F, 71 X   
12 M, 53  X  
13 M, 67   X 
14 F, 48 X   
15 M, 52 X   
16 F, 74  X  
18 M, 41  X  
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Patient number 1 showed a Gain of copy number on chromosome 3q26.32q26.33 of 404Kb in size 
(ISCN: arr[hg19] 3q26.32q26.33(178,853,968-179,258,128)x3) (Figure 3). 
The 13 genes included in the non-polymorphic duplication cover the 61% of all its extension.  
Among them, the OMIM gene PIK3CA (PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 
110-KD, ALPH, OMIM number#171834) is interrupted at its start point.  
the OMIM genes KCNMB3 (#605222), MNF1 (#608506), GNB4 (#610863) and the gene RP11-
360P21.2; SNORA25; LRRFIP1P1; ZNF639; RP11-255C15.3; RP11-145M9.4; AC007620.3; RP11-
145M9.2; MTHFD2P7 are completely duplicated but non-correlated with onco-haematological 
disorders.  
 
 
Figure 3 - Gain of 404 Kb on chromosome 3q26.32q26.33.  
 
 
 
Patient number 2 showed a 90% mosaic deletion on 7q22.1 of 41Kb in size, that encompass the 
interrupted CUX1 gene (CUT-LIKE 1, OMIM number#116896) and the entire SH2B2 gene (SH2B 
ADAPTOR PROTEIN 2, OMIM number#605300) (ISCN: arr[hg19] 7q22.1(101,919,899-
101,961,043)x1) 
Moreover, patient 2 showed also a significative LOH on entire chromosome X, both p and q arms of 29 
Mb (Xp22.33p21.1 start: 3,173,509; end: 32,400,206) and 77 Mb (Xq13.3q28 start: 75,876,163; end: 
153,390,510) in size respectively.  
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 A 
 B 
Figure 4 – Patient 2 mosaic deletion on chromosome 7q22.1 (Panel A) and LOH on chromosome X (Panel B) 
 
 
Patient number 4, represented in figure 5, showed a gain in 10p15.3p11.1 and a gain in 
10q11.21q26.3, resulting in trisomy of entire chromosome 10. (ISCN: arr[hg19]10p15.3p11.1(139,069-
39,075,180)x3; arr[hg19] 10q11.21q26.3(42,620,814-135,405,947)x3).  
                      
Figure 5 - Trisomy of chromosome 10  
 
 
 
Patients number 6 showed a gain of Chromosome 4: arr[hg19] 4p16.3p11(106,265-49,616,789)x3; 
4q12q35.2(52,718,771-190,925,290)x3 and a 66 Mb on Chromosome 11q LOH,  as shown in figure 6. 
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A 
 
 
 
 
 
 
B 
Figure 6 – Trisomy of chromosome 4 (Panel A); LOH of 66 Mb in chromosome 11q13.2q25  
                (start: 67,169,569; end: 133,167,706)(Panel B) 
 
Loss of heterozigosity encompasses 1412 gene, with a gene coverage of 57%.  
Among them, 90 genes are OMIM correlated to multiple diseases. 
 
Patient number 8 showed a LOH on chromosome 11q13.1q25 (start:65,485,307; end: 134,586,308), a 
trisomy of chromosome 13, and a loss of 632 Kb on chromosome 17: arr[hg19] 17q21.31(43,710,381-
44,342,442)x1. (Figure 7, panel A, B, C). 
 
Loss of heterozigosity encompasses 1412 gene, with a gene coverage of 57%; 90 genes are OMIM 
correlated to multiple diseases. 
Although the gene coverage is more than 90%,  the deletion is completely polymorphic. 
CNV on chromosome 17, includes 17 genes non correlated with haematological disorders: 
CRHR1-IT1; CRHR1; RP11-105N13.4; RP11-293E1.2; RP11-293E1.1; MAPT-AS1; SPPL2C; 
MAPT; RP11-669E14.4; STH; KANSL1; RP11-669E14.6; RNU7-101P; KANSL1-AS1; Y_RNA; 
RP11-259G18.2; RP11-259G18.3. 
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  A 
B
 C 
Figure 7 – LOH on chromosome 11q (Panel A), Gain of chromosome 13 (Panel B); Deletion of 632 Kb encompasses the 
MAPT gene on chromosome 17 (Panel C) 
 
 
 
Patient number 9 showed a LOH of 84 Mb, which encompasses the quite entire short arm of 
chromosome 2 (start:852,240; end: 84,177,129) (Figure 8) 
  
Figure 8 – LOH on chromosome 2 
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Patient number 10 showed a non-polymorphic duplication of 2,4 Mb in size on chromosome 10q25.1: 
arr [hg19]10q25.1(108,483,415-110,887,166)x3 (figure 9). 
This region encompasses 9 genes: SORCS1; RNA5SP325; RNA5SP326; RP11-215N21.1; PTGES3P5; 
RP11-163F15.1;RP11-655H13.2; MAPKAPK5P1; RN7SKP278. 
SORCS1, interrupted at start point, is the only OMIM gene.  
 
 
Figure 9 - Duplication of genes located on chromosome 10q25.1 
 
 
Patient number 17 showed a not polymorphic duplication of 53Kb length on chromosome 4p16.3: 
arr[Hg19] 4p16.3(1,757,674-1,809,838)x3.  
This region includes the FGFR3 gene (FIBROBLAST GROWTH FACTOR RECEPTOR 3, OMIM 
number#134934) related to OMIM Morbib #100800. (Figure 10, Panel A)  
A Copy number gain of 82 Kb on chromosome 7q22.1 interrupt CUX1 gene (CUT-LIKE 1, OMIM 
number#116896), and duplicate the entire SH2B2 gene (SH2B ADAPTOR PROTEIN 2, OMIM 
number#605300) (arr[Hg19] 7q22.1(101,879,884-101,961,043)x3). This regions is about 30% 
polymorphic. (Figure 10, Panel B). 
Patient 17 also presented a gain in 17q21.21 encompassing 5 genes: FMNL, SPATA32 and MAP3K14-
AS1 are duplicated and interrupted, CTD-2020K17.3; CTD-2020K17.4 are instead completely 
duplicated: arr [hg19] 17q21.31(43,313,986-43,334,920)x3 (Figure 10, panel C). 
A deletion of entire Chromosome Y was also detected by microarrays analysis: arr[hg19] 
Yp11.32p11.2(132,137-10,012,148)x0 (Figure 10, Panel D). 
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 A 
 B 
 C 
D 
Figure 10 – Gain on 4p (Panel A), Gain 7q (Panel B), gain 17q (Panel C), Loss of Y chromosome (Panel D). 
 
Patient number 19 showed, as only genomic aberration, the 102 Mb LOH on chromosome 
4q21.3q35.2. (start: 87,719,432 end:190,318,109). This region comprise 1242 gene.  
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 Figure 11 - LOH of 102Kb on chromosome 4 
 
 
 
Patient number 21 showed a trisomy of chromosome 8 (arr[hg19] 8p23.3p11.1(123,735-
43,803,539)x3;  arr[hg19] 8q11.1q24.3(46,942,962-146,147,478)x3) and a 80% mosaicism gain on 
chromosome 1q21.1q44 of 107Mb in size (arr[hg19]1q21.1q44(142,706,628-249,228,445)x3). this 
duplication includes 2547 genes (gene coverage 54%) (Figure 12, Panel A and B)  
A 
B 
Figure 12 - Trisomy 8 (Panel A) and Loss 1q (Panel B)  
 
 
Patient number 22 represented in figure 13 showed multiple complex genomic changes in 
chromosomes 5, 7, 12, 16 and 22 and demonstrated that abnormalities were indeed present. 
 
In Chromosome 4 a deletion of 17.7Mb in size (arr[hg19] 4q32.31q34.3(160,224,719-177,928,614) 
was detected. 5/183 genes deleted (GK3P; TLL1; PALLD; NEK1; HPGD) are related to OMIM 
disease (Figure 13, Panel A) 
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Chromosome 5 presented a deletion of 1245 gene of 80 Mb in size (arr[hg19] 5q14.3q34(86,951,953-
167,597,145), resulting in loss of more than one half q arm. (Figure 13, Panel B) 
Chromosome 7 is completely deleted: arr[hg19] 7p22.3q36.3 (579,941-159,124,478)x1. (Figure 13, 
Panel C) 
Chromosome 12 showed a loss of 11.74 Mb in size located on 12p13.2p12.1: arr[hg19] 
12p13.2p12.1(10,929,829-22,672,718)x1. (Figure 13, Panel D) 
Chromosome 16 showed a gain of 32.37Mb on p-arm: arr[hg19] 16p13.3p11.2 (99,414-32,470,683)x3;  
and a loss on q-arm: arr[hg19] 16q11.2q24.3 (46,511,147-90,053,103)x1 ). (Figure 13, Panel E) 
A 
B 
 C 
D 
E 
Figure 13 – Loss4q (Panel A), loss5q (Panel B), -7 (Panel C), loss12p (Panel D), Gain16p and loss16q (Panel E) 
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4.1.2 Group 2) AML subgroup with complex karyotype 
 
Conventional karyotype was performed at diagnosis in 4 patients with not well-defined AML and 
showed a complex karyotype with multiple rearrangements.   
 
In order to detect cryptic imbalances, CGH array 4x180K Oligo array Platform (Cytosure, OGT) and 
moleculare tests were performed at the same time.  
Table 8 shows the main imbalances and, when present, the corresponding new fusion gene due to 
translocation.   
 
 
SEX 
and 
AGE 
CNV GAIN SIZE % POL CNV LOSS SIZE % POL 
FUSION 
GENE OUTCOME 
M, 32 // // // 17p11.2-p11.1 17q21.2 
1 Mb 
1,8Mb 
27%           
8% 
STAT5B-
RARA 
CR, BMT. In 
follow up 
M,83 // // // 
2p14-p11.2 
11p13 
11q12.1-q23.3 
15,72Mb 
1,123Mb 
61,1Mb 
0% ? D 
M, 66 
7p22.3p15.1 
7p14.3p12.3 
7p12.1q31.1 
23Mb 
13,8Mb 
49Mb 
0% 
4q32.3q34.1 
5p15.33p15.31 
6q24.2q27 
7p15.1p14.3 
7p12.3p12.1 
9p21.3q34.3 
12p13.31p12.3 
13q11q34 
20p12.3p11.23 
Xq26.3q28 
7,8Mb 
7Mb 
25,6Mb 
4,7Mb 
3,5Mb 
119,5Mb 
7,4 Mb 
95,3Mb 
12,9Mb 
19,3Mb 
0% // CR, RE, D 
M,24 // // // 
5q14.2q15 
5q21.1q32 
5q33.1q35.1 
5q35.1q35.3 
5q35.3 
5q35.3 
12 Mb 
51Mb 
23Mb 
4Mb 
3Mb 
3,7Mb 
0% // n.d. 
Table 8 – AML-subtypes patients and the main molecular imbalances  
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Case 1) APL with STAT5B-RARA fusion gene 
 
A 32-year-old man was admitted to our Hematology Department complaining for fever, cellulitis of the 
right leg and palpable hepatosplenomegaly.  
Examination of peripheral blood indicated a white blood cell count of 6.8 x109/L (neutrophils 0.5 
x109/L; lymphocytes 2.7 x109/L; monocytes 0.4 x109/L; blasts 8%), hemoglobin 7.4 g/dL, platelet 
count 129 x109/L. The bone marrow aspirate showed a 90% blasts infiltration of medium size 
promyelocytes.  
QFQ-banding cytogenetic analysis (Figure 14) on 24 metaphases showed loss of Y chromosome and 
structural rearrangements of chromosome 17 consisting in a pericentric inversion (p11.2q21) and in a q 
arm deletion (q21) (24 metaphases) (Figure 15, Panel A); normal male karyotype was found in 5 
metaphases. 
FISH analysis confirmed the correct position of telomeric probe signals (Figure 15, Panel B ) and 
pericentric inversion of chromosome 17 with RARA probe on 17p arm (Figure 15, Panel C). 
 
 
 
Figure 14 – QFQ-banding karyotype of patient 
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Figure 15 -  Chromosomes 17 and der(17)inv(17)(p11.2q21)del(17)(q21) (Panel A); FISH with pretelomeric probes Tel 17p 
(green, D17S2199), Tel17q (red, D17S2200) (Panel B); FISH with RARA probe (green), PML probe (red) and telomeric 
17p probe (red) (Panel C).  
 
 
We also performed Array-CGH analysis on leukemic cells, in order to better redefine breakpoint region 
and cryptic imbalances. Two CNVs were detected (Figure 16)  
 
- The first CNV was a 1,01 Mb deletion in 17p11.2p11.1 from start point 21,195,578 to end point 
22,205,792. This CNV is polymorphic for 27% of its extension (DGV database) and overlaps 3 
OMIM genes: MAP2K3 (OMIM number #602315) interrupted by the start point, KCNJ2 
(OMIM number #602323) and KCNJ18 (OMIM number #613236) that is completely deleted.  
- The second CNV is a 1,827 Mb deletion in 17q21.2 from 38,526,212 to 40,353,672. This 
deletion is constitutionally polymorphic for only 8% of its extension, includes 46 full deleted 
OMIM gene and interrupts STAT5B gene, within the exon ENSE000012935555. 
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Figure 16 -  Array CGH-180K 17p11.2-p11.1 and 17q21.2 deletions. 
 
 
 
 
The final karyotype resulting from cytogenetic, FISH and array-CGH investigations, according to 
ISCN 2013,  was: 
 
45,X,-Y,der(17)inv(17)(p11.2q21)del(17)(q21)[24]/46,XY[5].ish 
der(17)(p13)(D17S2199+)(p11.2)(RARA+)(q25)(D17S2200+). 
arr[hg19] 17p11.2p11.1(21,195,578-22,205,792)x1,17q21.2(38,526,212-40,353,672)x1   
 
 
Molecular analysis for PML-RARA [t(15;17)], RUNX1T1-RUNX1 [t(8;21)], CBFB-MYH11 
[inv(16)], FLT3-ITD and NPM1 were normal. 
 
Molecular and array-CGH results allowed us to hypothesize the presence of a STAT5B-RARA fusion 
gene.   A specific DNA fragment was amplified with the following primers for STAT5B-RARA: 
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STAT5B-F1: 5’-GCCGTGCCTGACAAAGT-3’; STAT5B-F2: 5’-ACATCTCAAGCCTCATTGGA-
3’; RARA-R1: 5’-TCTTCTTGTTTCGGTCGTT-3’; RARA-R2: 5’-TGTTTCGGTCGTTTCTCAC-3’. 
The PCR primers were designed using Primer-BLAST. 
The nucleotide sequencing analysis of the amplified DNA demonstrated STAT5B-RARA fusion. 
Sequencing analysis showed the presence of a 390 bp PCR fragment encompassing the fusion between 
exon 15 of STAT5B with exon 4 of RARA (Figure 17 ) 
 
 
 
Figure 17 – STAT5b and RARA fusion gene  
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Case 2) APL with t(4,17)(q12;q21) 
 
A 83 years old man was admitted to our Hematology department for pancytopenia and suspected APL. 
According to the guidelines, the final karyotype on non-stimulated metaphases was: 
46,XY,t(4;17)(q12;q21),del(11)(q12)[20]/46,XY[1].  
In order to exclude an unbalanced translocation between chromosomes 4,17 and 11, we performed 
CGH-array.  
Molecular karyotype shows:  
- a deletion on 2p14-p11.2 of 15,726Mb in size (arr[hg19] 2p14-p11.2(67,918,036-83,644,034)x1) 
which encompasses 78 OMIM gene. The maximum overlap between deletion and polymorphic region 
is 7% of total length.  
- a deletion in 11p13 and 11q12.1-q23.3 of 1,123Mb and of 61,1Mb in size respectively (arr[hg19] 
11p13832,277,043-33,400,760)x1; arr[hg19] 11q12.1-q23.3(56,482,185-117,566,772)x1). 477 OMIM 
gene resulted deleted (Figure 18)  
Figure 18 - Molecular Karyotipe 
(on the left) and enlargement of chromosome 11. ( Red line= deletion, Green Line= duplication) 
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Case 3) Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN) 
 
Cytogenetic analysis on peripheral blood with more than 30% of circulating blasts showed a 
monosomy of chromosome 9, typical cytogenetic abnormality of this AML subgroup, and 13 
monosomy.  
According to ISCN 2013, the final karyotype of 20 non-stimulated metaphases was: 
45XY, del(12)(p13), -13, del(20)(p11). 
 
CGH-array analysis on leukemic cells showed several CNVs, as reported in table 9 
 
Copy Number Variation Size (Mb) 
4q32.3q34.1(165,987,693-173,843,632)x1 7,8 
5p15.33p15.31(2,539,901-9,630,103)x1 7  
6q24.2q27(145,440,205-171,025,493)x1 25,6  
7p22.3p15.1 (41,117-28,367,895)x3 23 
7p15.1p14.3(28,390,641-33,098,362)x1 4,7 
7p14.3p12.3(33,114,898-47,111,872)x3 13,8 
7p12.3p12.1(47,134,426-50,634,897)x1 3,5 
7p12.1q31.1(50,653,308-113,071,134)x3 49,2 
9p21.3q34.3(21,218,577-141,102,496)x1 119,5 
12p13.31p12.3(7,778,791-15,692,368)x1 7,4 
13q11q34(19,066,607-115,105,783)x1 95,3 
20p12.3p11.23(7,782,442-20,747,605)x1 12,9 
Xq26.3q28(135,702,412-155,046,701)x1 19,3 
Table 9 - Copy Number Variation and corresponding size, expressed in Mega Bases (Mb) 
 
It is interest that genetic imbalance of this rearrangement showed a chromothripsis 
involving chromosome 7 (Figure 19). 
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Figure 19 - Molecular karyotype of onset BPDCN.  ( Red line= deletion, Green Line= duplication) 
 
 
 
 
 
 
 
 
 
53 
 
Case 4) AML with tetraploid karyotype  
 
The first cytogenetic examination revealed in 20/20 analyzed metaphases of the bone marrow cells, a 
tetraploid range with 92 chromosomes and several genetic abnormalities.  
Final Karyotype, according to ISNC 2013 was:  
92, XXYY, del(5)(q11.1), del(5)(q21),t(15;17)(q22;q21)x2 [20]. 
Molecular analysis detected PML-RARA fusion gene due to t(15;17)(q22;q21).  
We performed Array CGH in order to better define a deletion on chromosome 5.  
 
Microarrays analysis detected 6 copy number losses on chromosome 5, as reported below in figure 20 
The balanced translocation t(15;17) was not detected by this technique. 
 
        Figure 20 - Chromosome 5 copy number deletions, size expressed in MegaBases and number of genes deleted. 
 
 
54 
 
4.2 POST KIDNEY TRANSPLANTED PATIENTS  
 
In order to evaluate constitutional CNVs that might predispose to post-transplantation 
lymphoproliferative disease, we analyzed twenty-two renal transplated patients at Pedriatric 
Nephrology Unit  IRCCS Giannina Gaslini Institute, Genoa.  
Samples from this patients were crio-preserved at Pediatric Hematology/Oncology Department, 
Fondazione IRCCS Policlinico San Matteo, Pavia of San Matteo Hospital (Pavia).  
 
This study includes a range of pediatric-adolescent patients, male and female, with different age, 
ranging from 3years old to 18years old, and all EBV negative at time of transplantation (Table 10) 
 
Patients were further grouped into four main categories, based on clinical post-transplantation 
manifestations (Table 11): 
Group 1:  patients with PTLD (number: 10, 11, 12, 13, 14, 15, 16, 17);  
Group 2: patients without PTLD and EBV- High Viral Load (more than 1000 copies/ml). This group is 
correlate to high risk to develop the onset of lympoproliferative disease (number: 4, 9, 20, 22); 
Group 3: patients without PTLD and EBV Low Viral Load (less than 1000 copies/ml)(number: 5, 7, 
19,); 
Group 4: patients with absence of clinical manifestations (number: 1, 2, 3, 6, 8, 27, 30). 
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PATIENT 
SEX, 
AGE 
EBV status after 
transplantation  
NEG= Negative  
POS= Positive 
REASON OF RENAL 
TRANSPLANTATION 
CLINICAL 
MANIFESTATION /  
Viral Load  
1 F, 17 NEG  nephronophthisis  //  
2 M, 15 NEG  Alport syndrome  // 
3 F, 8 NEG  family focal 
glomerulosclerosis 
// 
4 F, 15  NEG  hemolytic uremic syndrome High Viral Load  
5 M, 14  POS  renal hypodysplasia Low Viral Load  
6 F, 4 NEG  Congenital nephropaty post 
FANS  
 //  
7 M, 12  POS  n.d Low Viral Load  
8 M, 18 NEG  Recessive polycystic kidney // 
9 M, 16 POS  n.d High Viral Load  
10 M, 16  n.d n.d PTLD  
11 M, 5 NEG  diffuse mesangial sclerosis PTLD  
12 F, 3 NEG renal dysplasia PTLD  
13 F, 11  NEG  nephronophthisis PTLD  
14 M, 11  POS  Alport syndrome PTLD  
15 M, n.d NEG  n.d PTLD  
16 M, 4  n.d n.d PTLD  
17 M, 4  NEG  n.d PTLD  
18 M, 15 NEG  focal glomerulosclerosis //  
19 M, 12 POS  Reflux nephropathy Low Viral Load  
20 M, 9 POS  Lesch-Nyhan Syndrome High viral load 
21 M, 26?? NEG  renal hypodysplasia  // 
22 F, 13 POS Bor syndrome  High Viral Load  
Table 10 - Coort of Kidney-transplanted patients 
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Table 11 – Schematic rappresentation of groups based on clinical post-transplantation manifestations. 
 
We performed a whole genome analysis by using 4x180K array platform (OGT, Cytosure) and we 
detected all the CNV listed in the table below.  
 
 
 
 
 
 
 
 
 
 
 
 
Group 1 2 3 4 
Clinical manifestation PTLD High Viral Load Low Viral Load Control Patients 
Patient 10, 11, 12, 13, 14, 15, 16, 17 4, 9, 20, 22 5, 7, 19 1, 2, 3, 6, 8, 18, 21 
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Chromosomal  
Band   
 
PATIENTS  
1 2 3 4 5 6 7 8 9 10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
1p21.1  x     x  x x x   x  x   x x  x 
1q31.3                 x      
1p34.3               x        
1p36.13              x         
1p36.33 x                      
1q21.1              x         
1q44              x         
1q31.1   x                    
1q31.3       x                
2p22.3                     x  
2p11.2p11.1   x                    
2p11.2     x                  
2q13 x            x x         
2q37.3 x x                     
3p24.3 x                      
3q26.1  x  x   x    x    x x x  x    
3q29             x          
4p11                  x     
4p16.1                x x      
4q13.2  x x x      x x x  x   x x  x   
4q22.3q23                 x      
4q31.2            x           
5p15.1    x                  x 
5p15.3          x        x   x  
5p13.2                     x  
5q13.2   x    x     x      x   x  
5q35.3  x                     
6p21.32           x            
6p22.2       x              x  
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Chromosomal  
Band   
 
PATIENTS 
1 2 3 4 5 6 7 8 9 10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
6p25.3         x      x     x  x 
6q27 x  x                    
7p21.3     x                  
7q22.1     x        x          
7q31.1      x                 
7q33                  x     
7q35    x    x  x          x x  
7q36.3     x x                 
8p23.1 x x x  x  x  x x x     x  x x    
8p11.22     x    x      x  x x   x  
8q21.13      x                 
9p13.1  x x      x x   x       x   
9p11.2   x       x   x         x 
9p21.3                   x    
9p22.2     x                  
9p23           x            
9p24.3    x  x            x     
9q12          x          x x  
9q13          x          x x  
10q21.1                   x    
10q23.1   x    x                
11p14.3 x                      
11p11.12   x                    
11q14.1     x                  
12p12.3                     x  
12q12              x         
12q14.2                x       
14q11.2 x   x  x   x   x        x   
14q32.33         x  x x x          
15q11.2 x  x x  x         x     x   
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Chromosomal 
band  
PATIENTS 
1 2 3 4 5 6 7 8 9 10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
15q11.1q11.2  x   x  x          x     x 
15q13.2                     x  
15q14   x         x           
15q26.3             x  x x       
16p11.2p11.1  x                   x  
16p11.2          x    x        x 
16p12.2    x                   
16q11.2                    x   
16q24.3     x                  
17q12               x        
17q21.31 x         x   x       x x  
18q21.1        x               
18q22.3       x                
20p12.3                   x    
20p13    x                   
21q22.11                x       
22q11.1  x          x           
22q11.2 x     x           x     x 
22q11.23q12.1               x        
Xp11.23                   x  x  
Xp22.33  x   x x x  x  x  x x  x  x    x 
Xq22.2 x                      
Xq11.1          x             
Xq26                    x   
Xq28            x           
Yp11.32  x       x       x  x     
Yq11.223  x   x  x x x       x x      
Yq11.23  x   x   x x       x x      
Yq11.23q12        x      x         
Table 12 – List of all genomic aberration detected by 180K oligo array platform 
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The most recurrent regions of genomic imbalance in our patients (CNVs) are summarized in the 
following chromosomal bands (Table 13)  
Ch
ro
m
os
om
al
 b
an
d 
PATIENTS 
Control Low Viral High Viral PTLD 
1 2 3 6 8 18
 
21
 
5 7 19
 
4 9 20
 
22
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
1p21.1  G       L L  L G G G G   G  G  
2q13 L                 L L    
4p16.1                      L L 
4q13.2  L G   L     L  L  G G L  G   G 
5p15.1           G   G         
5q13.2   G   G G  L        G      
6p25.3            L L G      G   
7q22.1        L          L     
8p11.22      G L G    G        L  G 
9p13.1            L   G   L     
14q32.33                G L L     
15q11.2 G  G G       G  G       G   
16p11.2              G G        
17q21.31       G      G  G        
22q11.2 G   G          G        G 
Xp22.33  G  L  G  L L   L/G  G  L  L L G   
Yq11.223  G   G   L              G 
Yq11.23  G    G   L              G 
Table 13 - Recurrent and significative CNVs in post-transplanted patients ( C= Control patients, LV=low viral, HV=High 
viral, PTLD) 
Here follow the most frequent anomalies detected in our cohort of patients. 
Patient number 14 presented both gain and loss of 1p21 chromosomal region. 
The CN loss is located on 1p21.1(103,517,424-104,284,282) is 776Kb in size and encompasses 15 
genes (COL11A1; SOD2P1; RP11-347K2.1; RP11-347K2.2; RP11-153F1.2; RP11-
153F1.1;RN7SKP285; RNPC3; AMY2B; ACTG1P4; AMY2A; AMY1A; RP5-1108M17.5; 
AMY1B;AMYP1)  
Among them, the OMIM gene COL11A1 (COLLAGEN, TYPE XI, ALPHA-1; OMIM 
number#120280) is interrupted between exon 3 and 4. This is a non-polimorphic region.    
 
61 
 
 
Figure 21- arr[hg19] 1p21.1(103,517,424-104,284,282)x3 
Patient number 1 and 13 carried a 496 Kb and 322 Kb deletions respectively, including the start/end 
point of NPHP1 (NEPHROCYSTIN 1, OMIM numbre#607100) related to Nephronophthisis 1, 
juvenile (#256100) (figure 22) 
 
Figure 22 - deletion in 2q13 encompassing NPHP1 gene in patient 3 (red line) and patient 13 (blu line) 
 
Four patients (patients High Viral 9, 20, 22 and patient PTLD 15) presented a genomic aberration 
involve chromosome 6p25.3.Patients number 9 and 20 reported a copy number variant Loss; patients 
15 and 22 reported a copy number variant Gain.  
This region is only 40Kb in length and also polymorphic, but DUSP22 gene (dual specificity 
phosphatase 22) is relevant and correlated with onco-hematological disorders.  
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Figure 23 -  arr[hg19] 6p25.3(259,531-293,497)x1 (Patient 9 violet line), arr[hg19] 6p25.3(259,531-293,497)x3(Patient 15 
blue line)  
 
 
Figure 24 -  arr[hg19] 6p25.3(259,531-293,497)x1 (Patient 20 red line), arr[hg19] 6p25.3(259,531-293,497)x3 (Patient 22 
blue line) 
 
 
Both copy number variant duplications and deletions affected chromosome 9p13.1.  
Size are very variable, as reported in Table 14.  
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Patient ISCN Notation Size 
Number of gene 
involved 
2 arr[hg19] 9p13.1(38,846,938-38,899,396)x3 52,46 Kb 1 
3 
arr[hg19] 9p13.1(38,791,655-38,951,375)x3  159,72 Kb 3 
arr[hg19] 9p13.1(40,491,851-40,632,479)x3  140,63 Kb  16 
10 arr[hg19] 9p13.1(38,768,412-38,951,375)x3  182,96 Kb  1 
9 arr[hg19] 9p13.1p12(38,789,216-42,010,037)x1 3,22 Mb 63 
13 arr[hg19] 9p13.1p11.1(38,822,497-47,312,281)x1 8,49 Mb  208 
Table 14 Aberrations in patients 2, 3, 10, 9 and 13 on chromosome 9.  
 
  
Patients 11, 12,13 reported  a CNVs in 14q32.33.  
Although this genomic alteration overlap a highly polymorphic region, it is relevant because includes 
several gene coding for IGHV (Table 15).  
 
Patient ISCN Notation Size 
Number of gene 
involved 
11 arr[hg19]14q32.33(107,148,712-107,182,881)x3 34,17 Kb 5 
12 arr[hg19]14q32.33(106,512,752-106,764,191)x1 251,44 Kb  33 
13 arr[hg19]14q32.33 (106,602,112-106,803,289)x1 201,18 Kb  33 
Tab 15. Characteristics of duplication and deletions in patients 11 and 13.  
 
Patient number 10 and 22 showed duplications on chromosme 16 (Figure 21). 
- Patient 10 showed two duplications, respectively of 173 Kb and 164,22 Kb in size (arr[hg19] 
16p11.2(32,573,813-32,746,861)x3) (arr[hg19] 16p11.2(33,107,015-33,271,235)x3). 
- Patient number 22 showed a duplication of 1,8 Mb in size (arr[hg19] 16p11.2(31,986,098-
33,786,268)x3). 
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Figure 25 - Duplications on chromosome 16. Patient 10 is rappresented in panel A, patient 22 in panel B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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5 – DISCUSSION 
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To overcome the limits of classical karyotype and FISH analysis, the Comparative Genomic 
Hybridization array (aCGH) is widely used to identify genomic imbalances in both constitutional and 
neoplastic cells and has revolutioned the field of clinical cytogenetics.  
 
Standard oncoematologic cytogenetics requires spontaneous dividing cells and, sometimes, results may 
be biased due to overcrowding of the cytogenetically normal cells compared to the abnormal ones.  
In addition cytogenetic analysis technique with QFQ/GTG banding has the limit of low resolution of 
about 10Mb. 
 
FISH analysis can be applied to metaphases or interphases nuclei and it can be used not only to detect 
numerical changes or structural aberration. The search for abnormalities is not intended to study the 
entire genome, but only the regions of interest, for which specific probes are available and its 
application needs a specific diagnostic suggestion.  
 
Array-based comparative genomic hybridization offers efficient high-throughput analysis of the entire 
genome for the identification of copy number variation/aberrations that occurr in clonal populations 
and would be undetected by conventional cytogenetic assays. It has improved resolution down to 
100Kb.  In addition SNP analysis is able to detect LOH/UPD (Loss of heterozygosity or Uniparental 
dysomic regions,) which are frequently involved in the cancer development.  
 
We applied aCGG + SNP analyses on 22 AML patients analized by classical cytogenetics and with 
normal karyotype (NK-AML) in order to detect cryptic somatic imbalances and in 4 AML patients with 
complex karyotype in order to redefine the cytogenetic result. 
 
Moreover, we performed aCGH on peripheral lymphocytes of a cohort of pediatric/adolescent patients 
that performed kidney transplantation, in order to investigate constitutional CNVs  with possible 
predisposing significance to lymphoproliferative disorders development (PTLD) that occurs in 20% of 
these patients.    
 
The purpose of these different studies is to detect by aCGH genomic alterations, acquired in AML or 
constitutional in PTLD patients, with possible oncogenic role. 
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AML with normal karyotype 
 
 About 50% of AML cases failed to show cytogenetic abnormalities (Akagi et al., 2008; Kim et al., 
2012; Bullinger et al., 2009). 
Therefore, one of the current challenges in the study of AML is to identify hidden or  cryptic genomic 
lesions that may be related to AML origin and patient outcome.  Array CGH with high 
oligonucleotides’ density in genes or genomic regions involved in hematological malignancies has been 
used to identify submicroscopic copy number variants across the genome.  
 
There are only few papers in literature about cryptic CNVs in NK-AML (Raghavan et al., 2005; 
Tyybakynoja et al., 2007; Akagi et al., 2008; Gupta et al., 2008; Bullinger et al., 2009; Kim et al., 
2012; Spina et al., 2015)  
 
Tyybakinoja et al., found cryptic CNVs in about 85% of NK-AML patients; Akagi et al. found CNVs 
and CNN-LOH in 49% of 30 NK-AML cases; Bullinger et al., studied 157 NK-AML patients and 
found CNVs in 49% of cases and CNN-LOH 12% of cases; Kim et al., studied 30  NK-AML patients 
in relation with treatment response and found CNVs in 76% of cases; Spina et al. studied  36 NK-AML 
patients and found CNVs in about 40% of cases.  
 
Gupta et al., in 454 patients of AML with normal or abnormal karyotype and found non-random 
acquired LOH in 17% of cases. Raghavan et al., studied 64 AML patients and found CNN-LOH region 
in 18% of cases.  
 
All together these studies suggest the clinical relevance and the prognostic significance of CNVs/LOH 
lesions in NK-AML and  that  aCGH- SNPs studies in larger cohorts of cases should improve 
prognostic stratification of patients and may reveal new therapeutic targets.  
 
We performed  a retrospective study by CGH+SNP array 60K Hematological platform on 22 samples 
of primary NK-AML  at the onset of the disease.  
 
Diagnosis of de novo AML was established at the Hematology Department of our hospital.  
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FAB classification is available for Patients 1 (M5), Patient 7 (M4), Patient 8 (M2), Patient 13, 17, 18 
(M5) and Patient 22 (M0). 
 
QFQ-banding cytogenetic analysis was carried out on at least 20 non-stimulated bone marrow 
metaphases in each case. The following cytogenetic controls during the evolution of the disease always 
confirmed persistent normal karyotypes.  
 
Array CGH was applied to genomic DNA from bone marrow mononuclear cells and blasts, separated 
by Ficoll. Array CGH was also applied on cultured bone marrow-derived fibroblasts in cases with 
significant not polymorphic CNVs/LOH regions, in order to verify their somatic nature.  
 
At this purpose, we excluded the CNVs that are common polymorphic regions (data not reported in 
table 5 and 6) or CNVs that does not contain cancer correlated genes (loss of 17q21.31, Patient 8).  All 
the CNVs and LOH considered and discussed are not constitutional and they are present in 100% of 
cells, as indicate by Cytosure OGT analysis software, used in our laboratory. 
 
The aCGH results confirmed the normal karyotype found by cytogenetic investigations in 50% of cases 
(11 out of 22) but in the other 50% of the cases detected additional significant aberrations not found by 
cytogenetic analysis, according to the data reported by Akagi et al., 2008 and Bullinger et al., 2009.  
 
We found CNN-LOH in 5 out of 22 patients (about 25%). This rate is similar to data from literature 
(Akagi et al., 2008; Bullinger et al., 2009).   
 
Genomic findings  
 
In 50% of the case (11 out of 22 cases) CGH array analysis detected both somatic CNVs and /or LOH, 
which are variable in size from few Kb to several Mb.  
 
In 5 cases array CGH unexpectedly revealed some relevant aberrations, such as aneuploidies  +10 
(Patient 4), +4 (Patient 6), +13 (patient 8), -Y (Patient 17), +8  and big structural rearrangements 
leading to trisomy of entire 1q  (Patient 21), monosomy 7 , deletion of entire 5q, duplication of 16p and 
deletion of 16q  (Patient 22).  
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These results are surprising because these aneuploidies are commonly dectected by cytogenetic 
analysis on leukemic bone marrow cells, but in this study a normal karyotype was diagnosed on at least 
20 metaphases in all cases, both at onset and during the subsequent cytogenetic monitoring of the  
disease. Moreover, these changes are known to be characteristic of AML subtypes, and some of these (-
7, -5q, +8, +13, -Y) have a specific diagnostic/prognostic and therapeutic value (Mitelman database). 
 
The reason of the great discordant results found by cytogenetic and aCGH analysis is not clear. 
 
One possible interpretation is that Ficoll-gradient applied on bone marrow samples used for DNA 
estraction to aCGH, selects mononuclear cells and blasts, thus CGH array was performed on selected 
cells that differs from the cell pool cultured for cytogenetic analysis.  
 
Otherwise, another interpretation of this discrepancy, is that the lack of cytogenetic evidence of such 
abnormalities may be related to low mitotic index of  such leukemic clones. 
 
We cannot exclude an hypothetical influence of additional CNVs or LOH on the  proliferation index of 
clones with aneuploidies or great imbalances.  
 
We cannot confirm the results with interphase FISH analysis because in this retrospective study no 
material were still available.  
 
Wrong interpretations of results by aCGH software analysis were excluded. 
 
 Trisomy 10 as sole abnormality (patient 4) is reported in 0.2% to 0.5% of AML cases but probably its 
frequency is underestimated. Trisomy 10 has been, however, described in all of the FAB AML variants 
except M3 and especially in M2 . Genes involved are unknown and the hematological and clinical 
features associated with this finding have not yet been clearly defined (Mitelman database; Kwong YL 
et al., 1993). 
 
  
 
70 
 
Trisomy 4 is another rare chromosomal abnormality in AML, occurring in less than 1% of cases.  
Although its prognostic relevance has been frequently debated, its association to outcome remains 
unclear, because of  the rarity of trisomy 4 as an isolated abnormality (Chilton L et al., 2016).  
 
Trisomy 13 is a rare chromosomal abnormality in AML with incidence rate of less than 1%.  It has 
been reported that trisomy 13 is strongly associated with presence of RUNX1 mutations and a high 
expression of FLT3 mRNA correlated to poor prognosis (Silva FP et al., 2007). 
 
Trisomy of chromosome 8, monosomy 7, monosomy 5q, loss of  sexual chromosomes are, on the 
contrary, often involved in AML (Mitelman database) and of well defined prognostic significance.  
 
  
About the structural abnormalities found, the duplication of all or part of the long arm of chromosome 
1 (Patient 21) is one of the most frequent chromosomal abnormalities in human neoplasia. It has been 
reported in patients with various myeloproliferative conditions, including AML. Although 
cytogenetically heterogeneous, duplication of the 1q21-1q32 segment is most commonly observed, 
indicating that certain chromosome 1 regions might harbor genes implicated in oncogenesis. Among 
them, the expression of CKS1B gene is elevaled in multiple cancer and is associated with poor 
prognosis. 
 
Gain of chromosome 1q is likely implicated in neoplastic processes by a gene dosage effect. Whether 
appearance of 1q duplication may be sufficient as the sole anomaly to promote leukemogenesis is 
unclear, as well as it’s role in cytotoxic therapy. Patient 21, also showed a molecular mutation of 
NMP1 gene. All these anomalies taken together probably contributed to resistance to chemotherapy, 
although NMP1 gene is a favorable prognosis marker  
 
Trisomy of entire 16p and a monosomy of entire 16q are present in patient 22 togheter with the others 
abnormalities (-7, -5q, loss 4q32.1q34.3, loss 12p13.2p12.1). Total or partial trisomy/monosomy of 
chromosome 16 are not currently described in AML cases, but may be a new cryptic abnormality. 
Patient 22 showed a very complex molecular karyotype: in addition to monosomy 7, monosomy 5q, 
trisomy 16p and monosomy 16q, the patient showed the deletion of 12p13.2p12.1. 
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Cytogenetic abnormalities involving the short arm of chromosome 12 have been documented in a wide 
variety of hematopoietic malignancies, including AML (Kobayashi, H et al., 1994)The reported 
deletion encompass the CDKN1B and ETV6 genes. A minimal interstitial deletion region is described, 
involving ETV6 and CDKN1B genes;  
 
CDKN1B, is a cyclin-dependent kinase inhibitor that blocks the cell cycle in the G0/G1 phase upon 
differentiation signals or cellular insult. CDKN1B also regulates cell motility and apoptosis (Cuesta R 
et al., 2009). Homozygous deletion of CDKN1B is rare (Mietelman Database) 
 
ETV6 is frequently deleted in hematological malignancies; the deletion of the normal (untranslocated) 
ETV6 allele in the presence of a translocation affecting ETV6 is quite frequent, notably in patients with 
ETV6-RUNX1, ETV6-NTRK3, ETV6-ABL1, ETV6-ACSL6 and ETV6-STL fusion. Deletion of an 
ETV6 allele has also been observed in the absence of rearrangement of the second allele (Mitelman 
database). Hemizygous interstitial 12p deletion is found in 10% of cytogenetically normal AML 
(Mitelman database, Feurstein S et al., 2014; Andreasson P et al., 1997) 
 
The deletion of 17 Mb on Chromosome 4 seems to be not involved in specific onco-hematological 
events, but all these finding taken together are probably the cause of the resistant to therapy of the 
patients.  
 
About LOH findings, in two cases (Patient 6 and 8) the same LOH of the quite entire q arm of 
chromosome 11 is present, as additional aberration to trisomy +4 and +13, respectively.  LOH on 11q 
is one of  the most recurrent finding in myeloid malignancies (Dunbar et al., 2008). Among several 
candidate genes on 11q the proto-oncogene, CBL is relevant in the pathogenesis of AML. Mutation in 
exons 8/9 of CBL gene plays a role in human FLT3 downstream signalling (Sargin B et al., 2007) and 
homozygous CBL mutations were found in most 11q acquired UPD-positive myeloid malignancies.  
 
11q13.2q25. MLL gene, located on 11q23.3, is an important player in epigenetic regulation in AML 
(Jin S et al., 2010) and the N-terminal part of the MLL-protein is fused to more than 70 possible fusion 
partners (Tamai et al., 2010). A LOH in 11q encompassing MLL gene was reported also in Gupta et al.  
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Patient number 2 showed a LOH of chromosome 2p, and no other chromosomal abnormalities or genic 
mutation: the meaning of this loss of heterozygosity in unclear. Also Gupta et al., identified  LOH on 
2q, suggesting that this region might be a novel candidate region involved in AML(Gupta et al., 2008). 
 
CNVs and LOH regions may have opposite effects on cells proliferations and patients’ outcome: 
Patient 6 with +4 and LOH 11q was resistant to therapy, Patient 8 with +13 achieved a complete 
remission. This interpretation of results need to be expanded in a wider range of case studies.   
 
Some cases showed, as only genomic abnormality,  little CNVs: gain 3q26.32q26.33 (patient 1),  loss 
7qq22.1 (patient 2), gain 4p16.3, gain 7q22.1, gain 17q21.31 (patient 17), loss 4q32.1q34.3 and loss 
12p13.2p12.1 (patient 22).  
 
Patient 1 showed a gain 3q encompassing PIK3CA gene, that provides instructions for producing the 
p110 alpha (p110α) protein, which is one subunit of an enzyme called phosphatidylinositol 3-kinase 
(PI3K). PI3K signaling is important for many cell activities, including cell growth and division 
(proliferation), movement (migration) of cells, production of new proteins, transport of materials within 
cells, and cell survival. PIK3CA is a transforming oncogene that was shown to have activating 
mutations in the commonly occurring cancers (Kang S et al., 2005). 
 
Patient 2 showed a cryptic loss on 7q22.1 of 41 Kb. This deletion encompasses CUX1 gene, which is 
normally highly expressed in multipotent hematopoietic progenitors and exhibits dynamic dosage 
changes during the course of differentiation.  
 
CUX1 gene encodes a homeodomain-containing transcription factor that regulates cell cycle 
progression and apoptosis.  
 
Deletion of a single allele of CUX1 is associated with haploinsufficiency transcript and protein levels 
(Megan E et al., 2013). 
 
This gene is tumor suppressor gene, frequently deleted in myeloid neoplasms (Megan E et al., 2013).  
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Two patients (Patient 1 and 2) showed NPM1 mutation. PIK3Ca duplication and CUX 1 deletion seem 
to have a negative prognostic significance, in contrast to positive meaning of NMP1 mutations. Both 
patients relapsed and we can assume that the effect of the altered gene dosage of PIK3Ca and CUX1 is 
prevalent on NPM1 mutation and plays a role in the outcome of the disease. 
 
Patient 10 showed a non significative gain in 10q25.1; this region does not contain gene involved in 
AML development.  
 
Patient 17 showed a 7q gain overlapping the just mentioned haploinsufficient CUX1 gene, a gain 4p 
encompassing FGFR3 and a gain 17q encompassing FMNL1.  
 
FGFR3 is constitutively activated in a large portion of epithelial, bladder and cervix cancers 
(Cappellen, D et al., 1999) but its role in leukemia has not been estabilished yet. Moreover, patient 17 
showed a gain in FMNL1 gene, located on 17q. This gene is over-expressed in a variety of 
hematopoietic malignancies (Favaro et al., 2003; Favaro et al., 2006; Schuster et al., 2007). 
 
The overexpression of  FGFR3 and CUX1 may have an irrelevant role in the progression of the disease, 
as shown by the complete remission of this patient. The correlation of triplication of FMNL1 gene and 
complete remission of the patient remains unexplained.  
 
There are not significant differences about clinical outcome (remission, relapse, theraphy response) 
between the group of patients without CNVs/LOH and patients with several CNV abnormalities.  
This may be due to the limited number of cases analyzed and probably to the fact the therapy was 
based on the finding of normal karyotype or molecular mutations. It is not possible to exclude that a 
different therapy  approach, based on the emerging cryptic abnormalities detected by aCGH, could 
modify the clinical evolution of the disease.  
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Inspite of the absence of clear prognostic implications, this study suggests the utility of aCGH analysis 
at onset of NK-AML patients because it may reveal unespected genomic abnormalities confined in 
cryptic clones, possibly influencing the therapheutic choises.  
 
Array CGH investigation reveal it’s great utility in 4 additional AML cases in wich cytogenetics 
identified complex chromosome aberrations not well definibles or absence in mitotic index.  
 
In patient 1 (group 2 table) aCGH array revealed two submicroscopic deletions 17p11.2-p11.1 and 
17q21.1  in a APL case that allow to define the rare APL variant with STAT5B-RARA fusion gene.  
As this rare variant shows resistance at the  classical  ATRA –ATO therapy, the identification by array-
CGH was of high clinical relevance. 
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) and 
constitutes 5-8% of all AML cases. About 98% of APL patients exhibits the specific chromosomal 
translocation t(15;17)(q24;q21) involving the promyelocytic leukemia gene (PML) on chromosome 
15q24 and the retinoic acid receptor alpha gene (RARA) on chromosome 17q21, resulting in an 
aberrant fusion gene PML-RARA. The hybrid protein inhibits the cellular differentiation and promotes 
an uncontrolled myeloid precursor cells proliferation (Pessina C et al., 2016, Rowley JD et al., 1977; 
Chen Z et al., 1992; Mistry AR et al., 2003; Grimwade D et al., 2000). 
 
Few patients with APL morphology present variant translocation involving RARA gene. The 
alternative partner genes include: ZBTB16 (zinc finger- and BTB domain-containing protein 16, 11q23 
chromosome band), NUMA1 (nuclear mitotic apparatus protein 1, 11q13), NPM1 (nuclephosmin, 
5q35), FIP1L1 (factor interacting with PAPOLA and CPSF1, 4q12), PRKAR1A (protein kinase A 
regulatory subunit type 1A, 17q24), BCOR (BCL6 corepressor, Xp11), and STAT5B (signal transducer 
and activator of transcription 5 beta, 17q21) (Pessina C et al., 2016).  
 
The variant cases characterized by ZBTB16-RARA and STAT5B-RARA fusions genes are notably 
resistant to ATRA (Melnick A et al., 1999) STAT5B-RARA is the most rare type of fusion transcript 
described so far with only 8 reported cases (Chen H et al., 2012; Melnick A et al., 1999; Arnould C et 
al., 1999; Gallagher Re et al., 2004; Kusakabe M et al., 2008; Iwanaga et al., 2009;Qiao et al., 2011; 
Jovanovic et al., 2011, Wang et al.,2015) two of wich showed the same del 17q. 
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This case suggest that a complete molecular analysis, including array CGH, is warranted in case of a 
morphological diagnosis of APL without the classical PML-RARA.  
 
In another APL patient (case 2- group 2) cytogenetic analysis showed a balanced translocation 
involving chromosome 4 and 17. CGH array, consented to better define the complex karyotype, permit 
to exclude the suspected involvement of chromosome 11 in the balanced translocation and to identifie a 
deletion 2p14-p11.2 of 15,726 Mb in size, not showed by conventional karyotype.  
 
Array CGH is of  relevant utility also when mitotic index is low and cytogenetic failed. Our patient 3 
(group 2) was affected by Blastic Palsmacytoid dendritic cell neoplasm, that is an aggressive 
hematopoietic malignancy AML type, derived from the precursor of plasmacytoid dendritic cells. 
There are no formal studies on the incidence of BPDCN in the general population. The few available 
data reported indicate that its overall incidence is extremely low, accounting for 0.44% of all 
hematologic malignancies (Bueno C et al., 2004).This tumor is characterized by a high frequency of 
cutaneous asymptomatic lesions at diagnosis. Predominance genomic losses affects chromosome 5q21, 
5q34, 12p13, 13q, 6q23, entire chromosome 9 (Leroux et al., 2002). 
 
Cytogenetic analysis showed only few chromosome abnormalities, such as monosomy 9 and 
monosomy13 (according to literature data).  
On the contrary Oligo-array technique defined a very complex genomic status with multiple 
rearrangements involving different chromosomes and reported in table 9, and Chromothripsis of 
chromosome 7.  
 
Chromothripsis is a recently described phenomenon  identified in cancer cells that produce catastrophic 
chromosome reorganization of one or a small number of chromosomes; it is been recently 
demonstrated that  Chromothripsis  generates marker chromosomes in AML and this phenomenon is 
associated with poor prognosis (Bochtler T et al Blood 2017, Jan 24). 
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Patient 4 had already shown cytogenetic abnormality on chromosome 5q and CGH array helped to 
better define the deletion. As expected, tetraploidy and the balanced translocation t(15;17) did not 
appear.  
 
As a whole, CGH array was clinically and biologically useful, as in two cases it helps to identify the 
rare APL variant with therapeutic conseguences  and in one case to identify complex abnormalities and 
chromotripsis phenomenon, which was not visible because of the lack of proliferation of leukemic 
cells.  
 
This highlights the importance of arrays in non-proliferant clones and also in complex cases. 
 
Inspite of the limited number of cases, this study suggests the clinical utility of aCGH at onset of the 
disease,  in AML patients with Normal karyotype and in patiens with low mitotic index or complex 
karyotype.  
 
Microarrays do not replace the conventional cytogenetic testing methodologies because they cannot 
detect truly balanced rearrangements or clones less than 20% of the cells, but it is evident that the 
incorporation of microarray testing into the routine clinical diagnosis of AML with normal karyotype at 
the time of diagnosis could be the right strategy required to enhance interpretation of the disease. 
 
Post- transplanted patients 
 
The second goal of this thesis through CGH array investigation is to identifie possible germline copy 
number imbalances (Constitutional CNVs) in pediatric patients tht performed kidney transplantation, in 
order to detect constitutional CNVs possibly correlated or predisposing to development of PTLD (post 
transplantation lynphoproliferative diseases).   
 
PTLD (PT-large B cell lymphoma, PT-DLBCL; PT-Burkitt lymphoma PT-BL; plasmoblastic 
lymphoma, PT-PBL) are a serious complication and appear in about 20% of transplanted patients.  
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EBV infections or its reactivation and immunosuppression are considered as predisposing factors, 
nowadays, there are no data regarding the finding and the impact of  constitutioal CNVs on the 
development of PTLD.  
A cohort of 23 pediatric/adolescent patients kidney transplanted for various disease, such as 
Nephronophthisis juvenile and renal displasia/hypodisplasia, were explored in order to investigate 
constitutional CNVs. 
 
Genomic DNA was taken from pre-transplantation T-lymphocytes.  
 
Patients were divided into four groups: 
- group 1: patients that developed PTLD (number: 10, 11, 12, 13, 14, 15, 16, 17);  
- group 2: patients that do not developed  PTLD and have EBV- High Viral Load. This group has a 
high risk of developing lympoproliferative disease (number: 4, 9, 20, 22);  
- group 3: patients without PTLD and  with EBV Low Viral Load (number: 5, 7, 19,);  
- group 4: patients with absence of clinical manifestations (number: 1, 2, 3, 6, 8, 27, 30). 
These two last groups are considered as controls. 
 
Clinical data and EBV-status were reported in table 9. 
We detected many CNVs, all reported in table 11.  
Table 12 illustrates recurrent CNVs found in the four different groups of patients.  
 
The total number of detected CNVs found in Controls/Low Viral load patients (first/second group) and 
High Viral load/PTLD (third/fourth group) do not show any significant difference.  
 
CNVs exclusively or mostly present in PTLD/EBV high viral load (PTLD-HV) group are:  
 
Duplication on chromosome 1p21.1 
 
This duplication is present in 7 out of 22 cases, not-equally spread in the four patients’ groups, as 
shown in Table 12.  
The duplication is present in 6 out of 12 patients (50%) of third/fouth group and only in 1 out of 10 
patients (10%)  of the control and low viral load groups.  
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Patient 14 shows a constitutional Gain of 776Kb, disprupting by its start point, the COL11A1 gene, 
suspected to be involved in carcinogenesis (Li et al., 2017).  
 
The other 5 cases (number 20 and 22 of Third group; number 10,11,16 of PTLD group and the control 
case number 2) show a smaller duplication of about 100Kb that include the polymorphic AMY-gene 
family but exclude COL11A1 gene.  
 
Deletions and duplications 6p25.3  
 
These small CNVs involve the DUSP22 gene, recently described as tumor soppressor gene in T-cell 
lymphoma subtypes (Mélard P et al. 2016). Four cases of  High Viral Load and PTLD patients, present 
both Gain (number 22,15) and Loss (number 9,20) of this region.  
In all cases DUSP22 gene is disrupted by the end-point of the CNV, in its initial region.  
This finding let us suppose a possible predisposing significance of this gene in the development of 
PTLD. However we can note that 3 out 4 patients nowadays have not yet developed PTLD, in spite of 
they present a High Viral Load. 
 
Duplication and Deletion on chromosome 14q32.33  
 
These CNVs are only present in PTLD patients and they are recurrent in B cell malignancies. 
(Takashima et al., 1997; Urbankova et al., 2012). Our interesting finding let us suppose that both 
duplications and deletions of this chromosomal band constitutional predispose to lymphoproliferative 
disorders. 
 
Duplication on chromosome 16p11.2  
 
This aberration is present in 2 case: patient 22 is a High Viral Load and patient 10 is a PTLD. 
The duplication of this region is a genetic abnormality frequently observed in pediatric B cell 
lymphomas, DLBCL (Deffenbacher et al., 2012). 
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In these cases, the gene involved in duplication is TP53TG3, that is involved in TP53-mediated 
signaling pathway. Considering the nature of TP53 gene, a genomic imbalances of genes correlated to 
TP53 pathway, let us suppose a possible role in cancer predisposition.  
 
Patients number 1 and 13 present an homozygous deletion of chromosomal region 2q13, encompassing 
NPHP1 gene, whose homozygous deletion is causative of 75% of Nephronophthisis juvenile, pathology 
affecting both two patients (OMIM numbers: 607000 and 256100 respectively). Patients 14 also 
presents a deletion in 2q13, but NPHP1 gene is excluded.  
 
Cases are spread equally in the two groups and do not correlate with PTLD. 
 
The results of this study, inspite of the limited casistic, let us make few consideration: 
 
CNVs containing  oncogenes  (Col11A,DUSP22,14q32, TP53TG3,or CNVs described in 
lynphoproliferative disorders are exsclusively or most frequently found in gropups of patient tha 
developed PTLA or with high viral load so at risk to develop it. 
The presence of the same CNVs in more than one group of patients suggest the probably necessity of a 
second genetic or environmental hit to start the neoplastic transformation and PTLD development.  
 
It will be interesting in the future to follow up cases with the same CNVs and absence of clinical 
manifestations, but with different Viral load. 
More case necessitate to conferme this suggestions. 
 
In conclusion our work confirm that array CGH is superior to other methodologies in detecting somatic 
chromosome aberrations not found with cytogenetics in primary AML defining their biogical and 
clinical significance and in exactly defining complex rearrangements with a single experiment. In 
addition, aCGH reveals constitutional CNVs that may be  predisponent to PLTLD development. 
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VARIABLE EXPRESSION OF SHOX AND KANK1 GENES IN A FAMILY CASE  
C. Pessina1 , A. Bussini2 , P. Granata1 , R. Righi1 , E. Meroni 1 R. Casalone1 
1?SSD Lab. Analisi, SMEL Citogenetica e Genetica Medica ASST Sette Laghi, Osp. di Circolo e Fond. 
Macchi, Varese  
2?Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale, Varese  
The short stature homeobox-containing gene (SHOX) is located in the pseudoautosomal region1 
(PAR1) of both sex chromosomes and it escapes from X-chromosome inactivation. SHOX gene 
alterations are associated with a wide phenotypic spectrum such as Idiopatic Short Stature, Leri-Weill 
Dyschondrosteosis and Langer Syndrome with variable penetrance also in the same family. Recently, 
SHOX duplications seem to be also correlated with Intellectual Disability (ID).  
KANK1 gene is located at chromosome 9p24.3 and it encodes a protein involved in cytoskeleton 
formation by regulating actin polymerization. Mutation in this gene have been associated so far with 
cerebral palsy, Spastic Quadriplegia type 2 and central nervous system development disorders. KANK1 
deletions have been described in cases with variable phenotype, such as Autism Spectrum Disorder, 
motor delay, ID and short stature.  
Here we describe the first family case with SHOX deletion and 9p24.3 microduplication. We 
performed Conventional cytogenetics analysis, array CGH and MLPA of SHOX gene. We detected a 
592 Kb deletion in Xp22.33 and a 279 Kb duplication in 9p24.3 including KANK1 gene. The deletion 
encompasses the entire SHOX coding region and also part of the regulatory upstream elements, while 
the start point of duplication is located within KANK1 gene. Since KANK1 has many alternative 
splicing sites, we can't leave out that this CNV may alter the expression of some transcripts.  
Father is carrier of both alterations and he has trasmitted SHOX deletion to all children while 9p24.3 
duplication only to 2/3. In this family SHOX gene deletion, as previously described in the literature, 
crossovers between X and Y chromosome during paternal meiosis resulting in an unusual inheritance. 
All family members with SHOX deletion present short stature or growth delay. KANK1 deletions are 
associated with dysmorfic features, ID, delay/absent speech and motor developmental. In our case, only 
one child shows such phenotype: we suppose an incomplete penetrance effect of KANK1 duplication, 
and that SHOX deletion together with KANK1 duplication may result in more severe phenotype. 
Anyway, phenotype-genotype correlation will be more clear during pubertal age, when clinical features 
are well define.  
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A NEW CASE OF MAYER-ROKITANSKY-KUSTER-HAUSER TYPE 2 SYNDROME WITH 
del(17)(q12). GENOTYPE- PHENOTYPE CORRELATION AND LITERATURE REVIEW  
P. Granata1 , C. Pessina1 , A.P. Genoni2 , C.M. Bulgheroni3 , J. Rampinini1 , R. Casalone1  
1?SSD Lab. Analisi-SMEL Citogenetica e Genetica Medica ASST Sette Laghi, Osp. di Circolo e Fond. 
Macchi, Varese  
2?Università degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese  
3?Dip. Materno Infantile, U.O.C. Ostetricia e Ginecologia, ASST Sette Laghi, Osp. F. Del Ponte, 
Varese  
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is characterized by anomalies of genital tract 
ranging from upper vaginal atresia to total mullerian agenesis with urinary tract abnormalities (OMIM 
277000). It’s incidence is about 1/5.000 newborn females. Affected women show 46,XX normal 
karyotype. MRKH may be isolated (MRKH Type 1- OMIM 277000) and comprises CAUV 
(Congenital Absence of Uterus and Vagina) and mullerian aplasia, or associated, in about 40% of 
MRHK patients, with renal, skeletal (mainly vertebral) malformations, hearing defects and, more 
rarely, cardiac anomalies (MRKH Type 2 or MURCS association- Mullerian duct aplasia, Unilateral 
renal agenesis and Cervicothoracic somite anomalies, OMIM 601076; GRES - Genital, Renal, Ear, and 
Skeletal when applied to both sexes). During last years, many cases of MRKH Type 2 and additional 
altered phenotypes have been published. The additional clinical traits are different and the most 
recurrent are MODY5 (Maturity-Onset Diabetes of the Young Type 5 OMIM 137920), facial 
dysmorfisms, moderate intellectual disability. Gene point mutations in CFTR, WNT4, TBX2, LHX1, 
HNF1B genes, and few genomic im- balances (CNVs) particularly 17q12 and 16p11.2 losses, are 
reported.  
We describe a 17 years old female patient with a MRKH type 2 complex phenotype consisting in a 
new, not previously reported association of MRKH Type 2, Autism Spectrum Disorder (ASD), 
moderate intellectual disability (ID) and psycho- motor delay. A 1,74 Mb 17q12 microdeletion, 
including 30 OMIM genes and MIR2909 gene, was identified by array CGH investigation. We review 
the literature and discuss the role of the del(17)(q12) in the MRKH phenotype.  
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p.Gly130Val MUTATION IN THE GJB2 GENE. A FAMILIAR DOMINANT HEARING LOSS 
WITHOUT SKIN MANIFESTATION  
A. Bussini2 , R. Righi1, A.P. Genoni3, C. Pessina1, E. Meroni 1 P. Granata1 , E.Cristofari4 R. 
Casalone1 
1?SSD Lab. Analisi, SMEL Citogenetica e Genetica Medica ASST Sette Laghi, Osp. di Circolo e Fond. 
Macchi, Varese  
2?Università degli Studi dell'Insubria, Dip. Medicina Clinica e Sperimentale, Varese  
3?Università degli Studi dell'Insubria, Dip. Biotecnologie e Scienze della Vita, Varese  
4?SSD ORL Servizio di Audiovestibologia, ASST Sette Laghi, Osp. di Circolo e Fond. Macchi, Varese  
Connexins are a multigene family proteins building gap junctions, intracellular channels found in all 
human body tissues, including nervous tissue, heart, muscle and skin. Several form of hearing loss are 
due to connexins mutations, but it has been demostrated that connexins are also involved in regulation 
of growth and differentiation of epidermis, so that many hereditary disorders, affecting both the 
epidermis and cochlea, have been linked to connexins mutations.  
In particular mutations of GJB2 gene (gap junction protein beta2), located on chromosome 13q12 and 
encoding the con- nexin 26 (Cx26), are involved in hearing loss diseases associated with skin problems 
such as Keratitis-ichthyosis deafness syndrome (KID), Palmoplantar Keratoderma with deafness 
(PPK), Hystrix-like ichthyosis deafness (HID), Vohwinked syn- drome, Bart-Pumphrey syndrome.  
Here we report a family (father and son) with sensorineural hearing loss, carrying?heterozygous 
p.Gly130Val mutation in GJB2 gene but, for the first time, without any dermatological problems. Only 
other two families in literature reported the same mutation, but associated with skin 
abnormalities.?p.Gly130Val is located on the second domain of GJB2 gene and it has been reported in 
patients with Vohwinkel syndrome, an autosomal dominant disorder characterized by congenital 
deafness, hyperkeratosis of the soles and palms, constrictions on the fingers and toes.?Proband is a 6 
years old male with post verbal congenital bilateral profound sensineural form of deafness, identified 
clinically at 3 years of age. His father have analogous phenotype, while the other family members 
(brother and paternal grandparents) don't show neither mutation in GJB2 or hearing loss.?We screened 
other genes involved in deafness (GJB6-d13s1830, GJB6-d13s1854, Mir-96, GJB3, GJA1, A1555G 
and A7445G) but no mutation were found.?GJB2 mutations associated with additional skin 
abnormalities have dominant inheritance pattern and very heterogeneous clinical features, also in the 
present family although there are no dermatological problems.?We can suppose that skin 
manifestations may be due to additional mutations or gene modifiers. Environmental factors during 
development or genetic background may also have a effect on phenotypic variation.  
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SHORT STATURE AND isoYp CHROMOSOME. A CASE WITH THREE COPIES OF SHOX 
GENE  
A. Bussini2 , C. Pessina1 P. Granata1 R. Righi1, A.P. Genoni3, M. Zanussi4, R. Casalone1 
1?SSD Lab. Analisi, SMEL Citogenetica e Genetica Medica ASST Sette Laghi, Osp. di Circolo e Fond. 
Macchi, Varese  
2?Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale, Varese  
3?Università degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese  
4?DIBIT2 Biologia Molecolare Clinica e Citogenetica, Osp. San Raffaele, Milano  
Short stature homeobox containing gene (SHOX) is located in telomeric region of both sex 
chromosome, in pseudoautosomal region 1 (PAR1). SHOX is one of the most important gene involved 
in scheletal growth and it is studied in patients with idiopatic short stature (ISS). The function of SHOX 
is dose depend: haploinsufficiency causes ISS and Lery Weill Dyscondrosteosys while triple dose of 
gene it seems linked to tall stature as in Klinefelter patients. However some cases with short stature and 
SHOX and/or regulatory elements duplications have been reported in literature. Authors have 
suggested that in these cases there is the lack of interaction between gene and regulatory sequences.  
Here we describe a 15 years old boy with three copies of gene resulting from a isoYp chromosome. 
The patient is the only child of non consanguineous parents. He shows short stature (146 cm, <3%ile,-
2SD) with normal values of GH (growth hor- mone), recurrent otitis, hearing loss, mild gynecomastia, 
normal external genitalia and spontaneous pubertal development. Cytogenetic analysis and FISH, 
performed in other centre, showed a derivative Y chromosome in all 100 metaphases analyzed. The 
final karyotype is 46,X,psu idic(Y)(pter->q12::q12->pter).ish psu idic(Y)(q12)(SRY++,DYZ1-). 
MLPA analysis of SHOX (P018-G1) confirmed the presence of three gene and nearby region copies. 
Furthermore, control probe located in the PAR2 (pseudoautosomal region 2) in q arm of both sex 
chromosome has resulted in single copy to demostrate the loss of Yq. No point mutations have been 
identified in coding regions by Sanger sequencing.  
Here we want to demonstrate the variable effect of triple dose of SHOX gene on final stature. In this 
patients gene and regulatory sequences are completely triplicate. We suppose that other gene on Yq or 
regulatory sequences are involved in the final phenotype. Array CGH analysis will help us to identify 
how many and which genes are deleted on Yq and will better define the break point in Yp.  
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Lo studio, condotto dal Gruppo di Lavoro SIGU di Citogenetica e Citogenomica, ha visto la 
partecipazione di 12 laboratori 
italiani che in totale hanno eseguito 4142 analisi postnatali mediante CMA (Chromosomal Microarrays 
Analysis). Ne ven- 
gono qui presentati i risultati preliminari, ricavati da una prima rielaborazione dei dati raccolti. 
L’indicazione all’analisi è stata: ritardo dello sviluppo nel 17% dei casi e associato a dismorfismi nel 
2%; sola disabilità 
intellettiva nel 12%, associata a dismorfismi nel 9%, a malformazioni nel 5%, a epilessia nel 4%; 
autismo nell’11%; presenza 
di sole malformazioni nell’8%; sospetta sindrome da micro-delezione/-duplicazione nel 7%; presenza 
di soli dismorfismi 
nel 3% e di sola epilessia nel 2% dei casi. Nel restante 20% dei casi le indicazioni erano rappresentate 
dalla combinazione 
di più segni clinici. 
Il cariotipo molecolare è risultato normale o con presenza di sole CNVs (Copy Number Variations) 
benigne in 2770 (67%) 
soggetti indagati ed anomalo in 1372 (33%). Le CNVs riscontrate, escludendo le benigne, sono state 
complessivamente 
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1744 in quanto alcune presenti contemporaneamente in uno stesso paziente. Di queste, il 33% è stato 
interpretato come 
clinicamente rilevante, l’11% come VOUS (Variants Of Unknown Significance) probabilmente 
patogenetica, il 25% come 
VOUS probabilmente benigna ed il restante 31% non è stato possibile classificarlo. Escludendo le 
categorie di indicazione 
all’analisi con un numero di pazienti indagati inferiore a 100, la percentuale più elevata di cariotipi 
molecolari anomali è stata 
osservata nei soggetti inviati per: dismorfismi (47%); sospetta sindrome da micro-delezione/-
duplicazione (40%); ritardo 
dello sviluppo (33%) e associato a dismorfismi (38%); disabilità intellettiva associata a malformazioni 
(38%), a dismorfismi 
(34%) o ad epilessia (28%), malformazioni (31%), sola disabilità intellettiva (27%); autismo (25%). 
L’elaborazione finale dei dati consentirà di trarre ulteriori informazioni e di raffrontarle con quanto 
riportato in analoghi studi 
presenti in letteratura 
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